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Introduction
This document will be regularly updated to include links and brief summaries of evidence on
therapies for COVID-19. We include a section on general recommendations as well as specific
recommendations and guidance by drug or drug combination.
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General
•

The environment inside the buildings matters for COVID spread. Humidifiers might help
Winter's cold, dry air makes respiratory viruses a triple threat. Warm, dry air also dampens the ability of
cilia, that line airways, to expel viral particles. The immune system's ability to respond to pathogens is
suppressed in drier environments. Humidifiers during the winter in buildings are recommended.

•

FDA authorizes blood purification device to treat COVID-19
FDA issued an emergency use authorization for a blood purification system to treat adult patients with
COVID-19 admitted to the ICU with confirmed or imminent respiratory failure.

•

Pharmacologic treatments for Coronavirus Disease 2019
A literature review was performed to identify current evidence regarding major proposed treatments,
repurposed or experimental, for COVID-19 and provide a summary of current clinical experience and
treatment guidance for this novel epidemic coronavirus.

•

Screening of FDA-approved drugs reveals 24 new candidates against SARS-CoV-2
3,000 FDA-and IND-approved drug library against SARS-CoV was screened to identify antiviral drug
candidates for the treatment of COVID-19. 48 drugs were selected and 24 drugs showed potential antiviral
activities against SARS-CoV-2.

•

A real-time dashboard of clinical trials for COVID-19
In a research letter in Lancet Digital Health, the authors from McMaster University present the
development of a R Shiny dashboard that tracks in real time more than 500 Covid-19 clinical trials recorded
at the Chinese Clinical Trial Registry, ClinicalTrials.gov, Clinical Research Information Service - Republic of
Korea, EU Clinical Trials Register, ISRCTN, Iranian Registry of Clinical Trials, Japan Primary Registries
Network, and German Clinical Trials Register.

•

Analysis of 189 COVID-19 trials: strengths and weaknesses
A retrospective analysis of 189 trials through February 20, 2020 was conducted. There were 69.3%
interventional studies, 21.7% observational studies, 5.3% diagnostic tests, and 3.7% other studies. Although
many COVID-19 studies include randomization in their design, the lack of additional double-blind and
placebo-controlled elements in their designs result in a less robust evaluation of intervention safety and
efficacy. Furthermore, similar or repeated research and small sample studies have possibly led to a
shortage of recruitable patients and become a barrier to the completion of large multicenter clinical trial
studies.

•

A comprehensive review on drug repositioning against COVID19
Old drugs that may be effective are from different pharmacological categories such as antimalarials,
anthelmintic, anti-protozoal, anti-HIVs, anti-influenza, anti-hepacivirus, antineoplastic, neutralizing
antibodies, immunoglobulins, and interferons. In vitro, in vivo, or preliminary trials of these drugs in the
treatment of COVID-19 have been encouraging, leading to new research projects and trials to find the best
drug/s. In this review, the authors discuss the possible mechanisms of these drugs against COVID-19.

•

Open access database of trials of drugs
A user-friendly, open access, online database of interventional trials of medicinal products is available to
monitor and rapidly identify products. The database, Covid19db, was published online. It has a high

number of duplicative/overlapping trials, in particular for some repurposed drugs, such as
hydroxychloroquine, azithromycin and tocilizumab, substantiating calls for better coordination and better
use of trial resources.

•

COVID-19 drugs interactions website
The website is developed to help practitioners to check for COVID-19 drug interactions (the link is here).

•

Global Coronavirus COVID-19 Clinical Trial Tracker
Canadian authors report the development of a real-time dashboard of clinical trials for COVID-19 available
at https://www.covid-trials.org/

•

Drug repositioning for treatment of COVID-19: a systematic review
Archives of Virology: 12 relevant studies were identified as eligible. Among the drugs reported 57 showed
some evidence of antiviral activity. Studies have reported the anti-SARS-CoV-2 activity of antitumor (16%;
9/57), antimalarial (7%, 4/57), and antibacterial (5%; 3/57) agents. 7 agents (chloroquine, tetrandrine,
umifenovir (arbidol), carrimycin, damageprevir, lopinavir/ritonavir) are in phase IV of clinical trials. Due to
the evidence of the anti-SARS-CoV-2 activity of various clinically available agents, drug repositioning stands
out as a promising strategy for a short-term response in the fight against the novel coronavirus.

Experimental drugs
•

A trial drug blocks the entry point for SARS-CoV-2 in organoids and can be a potential
treatment
A drug APN01 (hrsACE2) has inhibited the coronavirus load by a factor of 1,000-5,000 in vitro and will soon
be tested in clinical trials. The study shows the virus can directly infect and duplicate itself in stem cellsgrown blood vessels and kidneys.

•

Experimental drug EIDD-2801 shows promise against SARS-CoV-2 in animal models
The drug, called EIDD-2801 was able to hinder the COVID-19 coronavirus as it attempted to replicate itself
in human lung cells in test tubes, scientists reported Monday. It also hampered closely related
coronaviruses from reproducing in mice for several days and improved their lung functions.

•

Hypothiocyanite should be investigated for possible use against SARS-CoV-2
The hypothiocyanite ion (OSCN−)is part of the human natural protective system against infectious agents.
The reactive mixture LPO/H2O2/OSCN- already proved effective viricidal activity against a range of viruses
as HIV, herpes-simplex virus (HSV-1), adenovirus, echovirus and respiratory syncytial virus (RSV). Authors
claim in vitro testing of OSCN- is warranted.

Drug Development
•

Binding features of 10 FDA-approved drugs with the main protease from SARS-CoV-2
The authors document the binding features of 10 drugs that might target the protease. Conivaptan and
Azelastine are mainly involved in hydrophobic interactions with active site residues, and both maintain
close proximity to the protease binding pocket during simulation. These data need further in vitro and in
vivo evaluation to repurpose these drugs.

•

Targeting the SARS-COV-2 Life Cycle for drug development
In a research letter published in Travel Medicine and Infectious Disease, the authors argue that for
development of an effective therapy, good understanding of the viral life cycle is required, and that
different phases of the virus cycle could be simultaneously targeted for therapy.

•

Review of drug discovery and medicinal chemistry efforts against SARS-CoV2
A comprehensive review article in ChemMedChem highlights the past and present drug discovery and
medicinal chemistry efforts against SARS-CoV, MERS-CoV and COVID-19 targets.

Computationally Predicted
•

Top candidates for drug repurposing: Raltegravir, Paritaprevir, Bictegravir and
Dolutegravir
Two selected drug target proteins were screened against an in-house library of 123 antiviral drugs. After
extensive computational analysis, the authors proposed the above FDA-approved drugs as excellent lead
candidates.

•

Hypothesis: eat bitter substances and drugs to fight COVID-19
The authors searched currently available drugs that are agonists of TAS2Rs, which are hypothesized to
trigger host defense pathways. They identified many cheap, available, and safe medicines, such as
diphenidol, quinine, chloroquine, artemisinin, chlorpheniramine, yohimbine, and dextromethorphan, which
may target the most common symptoms caused by 2019-nCoV. They hypothesize a cocktail-like recipe of
existing bitter drugs may help doctors to fight COVID-19 and the general public may drink or eat bitter
substances, such as coffee, tea, or bitter vegetables, to potentially reduce the risk of infection.

•

Traditional Indian medicinal plants are proposed as novel therapeutic approaches
The authors discussed virus structure, symptoms of COVID-19, SARS, MERS and common flu, the
mechanism behind the infection and its immune response. Further, the current treatment options, drugs
available, ongoing trials and recent diagnostics for COVID-19 have been discussed. They suggest traditional
Indian medicinal plants as possible novel therapeutic approaches, exclusively targeting SARS-CoV-2 and its
pathways.

•

Computational drug design targeting the SARSCov-2 main protease reveals promising
results
Detailed 3D-structures of key virus proteins using computer-aided drug design techniques can be applied to
quickly identify promising drug repurposing candidates. Virtual docking screening revealed that several
approved drugs (Carfilzomib, Eravacycline, Valrubicin, Lopinavir and Elbasvir) are potential inhibitors of
SARS-Cov-2 protease.

Abiraterone
•

Bexarotene, Cetilistat, Diiodohydroxyquinoline, and Abiraterone as potential treatments
Pharmacological Research: The authors established a two-tier drug screening system that combines SARSCoV-2 enzyme-linked immunosorbent assay and cell viability assay and applied it to screen a library
consisting 1528 FDA-approved drugs. Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (antiparasitic), abiraterone acetate (synthetic androstane steroid), and bexarotene (antineoplastic retinoid)
exhibited potent in vitro anti-SARS-CoV-2 activity (EC50 1.13-2.01microM). Bexarotene demonstrated the
highest Cmax:EC50 ratio (1.69) which was higher than those of chloroquine, hydroxychloroquine, and
ivermectin. Thus, two-tier screening system is effective and identified potential COVID-19 treatments which
can achieve effective levels if given by inhalation or systemically depending on their pharmacokinetics.

Acalabrutinib
•

Cancer drug (acalabrutinib) may reduce symptoms of severe COVID-19
NIH Research Matters: Hyperinflammatory state in patients with severe COVID-19 is known as a cytokine
storm. Cytokines act as chemical messengers that help to stimulate and direct the immune response. But
when large amounts of cytokines are released in the body, it can be dangerous. Currently, there are no
proven treatment strategies for this phase of the illness. A research team led by Drs. Wyndham H. Wilson,
Louis M. Staudt, and Mark Roschewski at NIH’s National Cancer Institute (NCI) and Mihalis Lionakis at NIH’s
National Institute of Allergy and Infection Diseases (NIAID) tested the off-label use of a BTK inhibitor called
acalabrutinib to treat COVID-19. They carried out a clinical study of 19 patients with a confirmed COVID-19
diagnosis who required hospitalization and had low blood-oxygen levels and evidence of inflammation. Of
these, 11 had been receiving supplemental oxygen for a median of two days, and eight others had been on
ventilators for a median of 1.5 days.

•

Off-label observational study: acalabrutinib may calm the hyperinflammatory response
Science Immunology: Bruton tyrosine kinase (BTK) regulates macrophage signaling and activation.
Acalabrutinib, a selective BTK inhibitor, was administered off-label to 19 patients with severe COVID-19.
Over a 10-14 day treatment course, acalabrutinib improved oxygenation in the majority of patients, often
within 1-3 days, and had no discernable toxicity. C-reactive protein and IL-6 – normalized quickly in most
patients, as did lymphopenia, in correlation with improved oxygenation. At the end of acalabrutinib
treatment, 8/11 (72.7%) patients in the supplemental oxygen cohort were discharged on room air, and 4/8
(50%) patients in the mechanical ventilation cohort had been successfully extubated, with 2/8 (25%)
discharged on room air. Significantly elevated BTK activity, as evidenced by autophosphorylation, and
increased IL-6 production in blood monocytes was found from patients with severe COVID-19 compared
with blood monocytes from healthy volunteers.

ACEi/ARB
•

Outcomes on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers: a
meta-analysis
European Heart Journal - Cardiovascular Pharmacotherapy: Review of 16 studies showed conflicting
findings on severity and mortality in patients taking these drugs. In a pooled analysis of four studies, there
was a non-significant association of ACEI/ARB use with lower odds of developing severe disease vs. nonusers [OR = 0.81, 95% CI: 0.41-1.58, I2=50.52, P= 0.53). In a pooled analysis of 6 studies, there was a nonsignificant association of ACEI/ARB use with lower odds of mortality as compared with non-users (OR =
0.86, 95% CI = 0.53-1.41, I2 = 79.12, P = 0.55). It is concluded that ACEIs and ARBs should be continued in
COVID-19 patients, reinforcing the recommendations made by several medical societies. Additionally, the
individual patient factors such as ACE2 polymorphisms which might confer higher risk of adverse outcomes
need to be evaluated further.

•

Human recombinant soluble ACE2 shown to block early stages of SARS-CoV-2 infections
in lab
A study in Cell shows the results of human recombinant soluble ACE2 (hrsACE2) for blocking viral entry and
growth into cells. SARS-CoV-2 was shown to directly infect engineered human blood vessel organoids and
human kidney organoids, which can be inhibited by hrsACE2. This data demonstrates that hrsACE2 can
significantly block early stages of infections. Study design is limited by looking at early stages of infection,
thus cannot predict later stages of disease. They did not study lung organoids.

•

Angiotensin converting enzyme inhibitors and receptor blockers may have positive effect
on severity
A medRxiv preprint presents a meta-analysis of 5 available studies published before 4/21 and found a
statistically significant 44% reduction in odds of developing severe disease, and 62% reduction in odds of
death, in patients on an ACEi or ARB. It also found a non-significant 19% reduction in odds of hospitalization
among those on an ACEi or ARB. This adds to current knowledge confirming that it safe to use ACEi/ARB in
patients with COVID-19 and indicates that they may provide a clinical benefit.

•

In silico drug discovery suggest several new candidates targeting ACE-correlated genes
Researchers identified a network of 193 genes, 222 interactions and 36 potential drugs that could have a
crucial role for COVID-19 treatment. Among possible interesting drugs are Nimesulide, Fluticasone
Propionate, Thiabendazole, Photofrin, Didanosine and Flutamid.

•

No association of ACEI/ARBs with different outcomes in hypertensive patients
JAMA Cardiology: Retrospective, single-center case series (n=1178) hospitalized patients in Wuhan. There
were 362 patients with hypertension (30.7%), of whom 115 (31.8%) were taking ACEI/ARBs. The in-hospital
mortality in the patients with hypertension was 21.3%. The percentage of patients with hypertension
taking ACEIs/ARBs did not differ between those with severe and nonsevere infections (32.9% vs 30.7%; P =
.65) nor did it differ between non-survivors and survivors (27.3% vs 33.0%; P = .34). Similar findings were
observed when data were analyzed for patients taking ACEIs and those taking ARBs.

•

OHDSI large-scale observational network study: ACEIs and ARBs confer no extra risk
MedRxiv preprint: An observational study, carefully designed to control for confounding via propensity
score adjustment and negative controls, studied COVID-19 infection risk and outcomes for over 1.1 million
people taking antihypertensive medications. The study showed that angiotensin converting enzyme
inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) conferred no risk or benefit for: 1) COVID-19
diagnosis; 2) COVID-19 hospitalization; 3) hospitalization with pneumonia and; 4) hospitalization with
pneumonia, acute respiratory distress syndrome (ARDS), acute kidney injury (AKI) or sepsis (PAAS). The
authors conclude there is no clinically significant increased risk of COVID-19 diagnosis or hospitalization
with ACEI or ARB use. Users should not discontinue or change their treatment to avoid COVID-19. OHDSI is
an international network of researchers and observational health databases.

•

A noncompeting pair of human neutralizing antibodies block Covid-19 virus binding to its
receptor ACE2
Science: The authors report isolation of four human-origin monoclonal antibodies—B5, B38, H2, and H4—
against the Covid-19 receptor binding domain (RBD) and cellular receptor ACE2 from a convalescent
patient. All four antibodies exhibited neutralizing activities against the virus with B38 and H4 showing
additive inhibition effect. Furthermore, B38 and H4 showed complete competition with ACE2 for binding to
the RBD while B5 and H2 showed partial or no competition, respectively. The authors conducted a
therapeutic study in a mouse model with results revealing that these antibodies can reduce virus titers in
infected lungs.

•

Cardiovascular disease, ACE/ARB therapy and mortality in Covid-19
Data on 8910 patients hospitalized with a diagnosis of COVID-19 were analyzed. Cardiovascular disease was
associated with an increased risk of in-hospital death. Neither the use of angiotensin-converting–enzyme
inhibitors nor the use of angiotensin-receptor blockers was associated with an increased risk of in-hospital
death.

•

ACEi and ARBs not associated with adverse events or death
Systematic review and meta-analysis did not find evidence of an increase in critical events and mortality in
hospitalized patients given these medications for hypertension.

•

In silico screening of natural phytochemical compounds against COVID-19
The authors created a phytochemical library of 318 phytochemicals from 11 plants which have been
reported as having antiviral, antibacterial or antifungal activity. It was subjected to virtual screening against
molecular targets; Main protease (Mpro) and Angiotensin-Converting Enzyme 2 (ACE2). The top 10
compounds were selected from each target.

Amlodipine
•

Benefits of nifedipine and amlodipine in elderly patients hospitalized for COVID-19
A retrospective chart review study showed that patients treated with a calcium channel blocker (CCB) were
significantly more likely to survive than those not treated with a CCB (P<.01; p=0.0036). CCB patients were
also significantly less likely to undergo intubation and mechanical ventilation (P<.01; p=0.0026). Nifedipine
and amlodipine were found to be associated with significantly improved mortality and a decreased risk for
intubation and mechanical ventilation in elderly patients hospitalized with COVID-19.

Antibody
•

A human monoclonal antibody blocking SARS-CoV-2 infection
This is the first report of a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell
culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer
potential for prevention and treatment of COVID-19.

•

Isolation of neutralizing antibodies from SARS-COV-2 infected individuals
Nature: Reports the isolation of 2 specific human monoclonal antibodies (MAbs) from a convalescent
COVID-19 patient. CA1 and CB6 demonstrated potent SARS-CoV-2-specific neutralization activity in vitro.
CB6 inhibited SARS-CoV-2 infection in rhesus monkeys at both prophylactic and treatment settings. Further
structural studies revealed that CB6 recognizes an epitope that overlaps with angiotensin converting
enzyme 2 (ACE2)-binding sites in SARS-CoV-2 receptor binding domain (RBD), thereby interfering with the
virus/receptor interactions by both steric hindrance and direct interface-residue competition. The results
suggest CB6 deserves further clinical translation.

Anticoagulants
•

Heparin anticoagulant therapy improves hypoxia in COVID-19 patients - Brazilian case
series
MedRxiv preprint: A non-randomized case series of 27 consecutive COVID-19 patients admitted to hospital
were treated with heparin in doses tailored to clinical severity, ranging from 1 - 2 mg/kg of enoxaparin BD.
PaO2/FiO2 ratio increased significantly over the 72 hours following the start of anticoagulation, from
254(SD 90) to 325(SD 80), p=0.013, and 56% of the patients were discharged home within an average time
of 7.3 (SD 4.0) days. Half of mechanically ventilated patients were extubated within 10.3 (SD 1.5) days. No
deaths or hemorrhagic complications occurred.

•

High doses of heparin may trigger severe thrombocytopenia in COVID-19 patients
A medRxiv preprint of a Wuhan hospital study investigated critical ICU patients (n=61), 41% of which had
severe thrombocytopenia (ST) with a platelet count (PLT) less than 50x109/L. 76% of patients with ST had a
platelet decrease of >50% and 96% died. Continuous renal replacement therapy significantly decreased PLT
in 81.3% of patients (n=16) causing a fatal outcome. A high level of anti-heparin-PF4 antibodies was
observed in most ICU patients. Heparin-induced thrombopenia (HIT) occurred in patients both with and
without heparin exposure, suggesting that spontaneous HIT may occur.

•

Anticoagulation alone is unlikely to protect from COVID-19 related morbidity and
mortality
In a propensity score-matched cohort study (N=3,772), 241 patients with COVID-19 were receiving
anticoagulation (AC), 672 receiving antiplatelet therapy, and 2,859 receiving neither AC nor antiplatelet
therapy. Propensity matching yielded 139 patients who received AC and 417 patients who did not receive
treatment with balanced variables between the groups. There was no statistically significant difference in
survival (p= 0.367) and time to mechanical ventilation (p=0.742) between the two groups. The HRs for allcause mortality, mechanical ventilation and hospital admission comparing AC versus no AC/antiplatelet
groups were 1.208 (95%CI: 0.750-1.946), 0.905 (95%CI: 0.571-1.435), and 1.027 (95%CI: 0.654-1.612),
respectively. The same analysis was then performed but comparing patients receiving antiplatelet therapy
to those receiving neither antiplatelet therapy nor AC prior to COVID-19. There was no statistically
significant difference in survival (p=0.997) and time to mechanical ventilation (p=0.256) between the two
groups. The HRs for all-cause mortality, mechanical ventilation and hospital admission comparing
antiplatelet therapy versus no AC/antiplatelet groups were 1.029 (95%CI: 0.723-1.466), 1.239 (95%CI:
0.807-1.901), and 0.989 (95%CI: 0.755-1.296), respectively.

•

Systemic anticoagulation associated with decreased in-hospital mortality among
hospitalized patients
This cohort study of NYC patients (n=2,773) used a multivariate proportional hazards model to show a
longer duration of anticoagulant (AC) treatment was associated with lower mortality (adjusted HR of 0.86
per day, 95% CI 0.82-0.89, p<0.001). The benefit was largest for patients receiving mechanical ventilation
as hospital mortality for those receiving AC was 29.1% (median survival 21 days) vs 62.7% (median survival
9 days) for those who did not. There was also a higher risk of bleeding for ventilated patients leading the
authors to conclude the risks and benefits of anti-coagulation need to be weighed.

Anti-platelet
•

Anti-platelet therapy might be effective in improving the ventilation/perfusion ratio
A proof-of-concept study in Italy matched 5 control patients with 5 SARS-CoV-2 patients having severe
respiratory failure requiring helmet continuous positive airway pressure (CPAP), who had bilateral
pulmonary infiltrates and a pro-thrombotic state identified as a D-dimer > 3 times the upper limit of
normal. Beyond standard of care, treated patients received 25 micro-g/kg/body weight tirofiban as bolus
infusion, followed by a continuous infusion of 0.15 micro-g/kg/body weight per minute for 48 hours. Before
tirofiban, patients received acetylsalicylic acid 250 mg infusion and oral clopidogrel 300 mg; both were
continued at a dose of 75 mg daily for 30 days. Fondaparinux 2.5 mg/day sub-cutaneous was given for the
duration of the hospital stay. All controls received prophylactic or therapeutic dose heparin, according to
local standard operating procedures. Treated patients experienced a mean (SD) reduction in alveolararterial O2 gradient of -32.6 mmHg (61.9, P = 0.154), -52.4 mmHg (59.4, P = 0.016) and -151.1 mmHg (56.6,
P = 0.011; P = 0.047 vs. controls) at 24, 48 hours and 7 days after treatment. PaO2/FiO2 ratio increased by
52 mmHg (50, P = 0.172), 64 mmHg (47, P = 0.040) and 112 mmHg (51, P = 0.036) after 24, 48 hours and 7
days, respectively. All patients, but one, were successfully weaned from CPAP after 3 days. This was not
true for the control group. No major adverse events were observed.

Antivirals
•

In silico molecular docking analysis reveal potential antivirals
Authors conclude that Zanamivir, Indinavir, Saquinavir, and Remdesivir are among the exciting hits on the
3CL(PRO) main proteinase. In addition, Flavin Adenine Dinucleotide (FAD) Adeflavin, B2 Deficiency

medicine, and Coenzyme A, a coenzyme, may also be potentially used for the treatment of SARS-CoV-2
infections. A The use of these off-label medications may be beneficial in the treatment of the COVID-19.

•

Machine learning suggests commercially available antiviral drugs that may act on the
SARS-CoV-2
HIV drug Atazanavir has highest predicted inhibitory potency against the SARS-CoV-2 3C-like proteinase,
followed by remdesivir, efavirenz, ritonavir, and dolutegravir.

•

No impact of adding antiviral therapies for COVID-19 Pneumonia
Researchers at the Shanghai Public Health Clinical Center report in the Journal of Medical Virology the
peer-reviewed results of a 7-arm randomized clinical trial on 184 COVID-19 patients. The 7 groups included
symptomatic treatment, arbidol, lopinavir/ritonavir, arbidol+lopinavir/ritonavir, interferon,
Interferon+lopinavir/ritonavir, and interferon+darunavir. No significant differences were found among 7
groups of treatments in terms of the proportion of patients with pneumonia resolution (P=0.151) or the
length of hospital stay (P=0.116). Thus, the inclusion of antiviral drugs in therapeutic regimens based on
symptomatic treatment had no significant additional impact on the improvement in COVID-19 patients.

•

Antiviral drug candidates target the SARS-CoV-2 main protease
In an article in Science, Chinese researchers reported the discovery of two lead compounds targeting the
SARS-CoV-2 main protease. Both exhibited antiviral inhibitory activity, and both had good pharmacokinetics
properties in vivo. One also exhibited low toxicity.

•

Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors
Journal of Biomolecular Structure and Dynamics: With the aid of bioinformatics and computational
modelling, 97 antiviral secondary metabolites from fungi were docked onto five SARS-CoV2 enzymes
involved in viral attachment, replication, post-translational modification, and host immunity evasion
infection mechanisms followed by molecular dynamics simulation and in silico ADMET prediction
(absorption, distribution, metabolism, excretion and toxicity) of the hit compounds. Thus, three
fumiquinazoline alkaloids scedapin C (15), quinadoline B (19) and norquinadoline A (20), the polyketide
isochaetochromin D1 (8), and the terpenoid 11a-dehydroxyisoterreulactone A (11) exhibited high binding
affinities on the target proteins, papain-like protease (PLpro), chymotrypsin-like protease (3CLpro), RNAdirected RNA polymerase (RdRp), non-structural protein 15 (nsp15), and the spike binding domain to
GRP78. Of the five top-scoring metabolites, quinadoline B (19) was predicted to confer favorable ADMET
values, high gastrointestinal absorptive probability and poor blood-brain barrier crossing capacities.

Arbidol
•

Effectiveness of arbidol for COVID-19 prevention in health professionals
Frontiers in Public Health: In an observational study, frontline health professionals with COVID-19 in China
(N=82) and the same amount of controls (N=82) in the uninfected group were included. 19 (23.2%)
patients in the infected group were administered oral arbidol, and 48 (58.5%) in the uninfected group (OR
= 0.214, 95% CI 0.109-0.420). The cumulative uninfected rate of health professionals in the arbidol group
was significantly higher than that of individuals in the non-arbidol group (log-rank test, chi(2) = 98.74; P <
0.001). 48 patients (58.5%) in the infection group were hospitalized, with a median age of 39 (31-49) years,
of whom 7 (14.6%) were prophylactically administered arbidol. 34 patients (41.5%) with mild symptoms
were treated outside the hospital, among which the median age was 34 (30-39) years, and twelve patients
(35.3%) took prophylactic oral arbidol. The hospitalization rate was significantly associated with age (P =
0.024) and oral arbidol administration (OR = 0.313, 95% CI 0.108-0.909). In the age-matched case-control
study, the hospitalization rate was not significantly associated with arbidol administration (P = 0.091).

•

Arbidol monotherapy may be superior to lopinavir/ritonavir in reducing viral load
Journal of Infection: Non-randomized retrospective Chinese study shows 16/16 people had full viral
clearance after 2 weeks on arbidol versus 19/34 on lopinavir/ritonavir. We compute 2-sided Fisher’s exact
test significance of 9.2x10-4. Interpret with caution as there were significant differences among the
treatment arms. Arbidol is only approved in China and Russia.

•

Antivirals do not reduce time of viral clearance, lopinavir/ritonavir delayed viral clearance
MedRxiv preprint: Guangzhou study examined 284 consecutive COVID-19 cases. 280 patients achieved viral
RNA clearance with a median length of 12 days (IQR: 8-16) after onset of illness. 66.1% of them had viral
RNA cleared within 14 days, and 89.3% within 21 days. Older age, severity of disease, time lag from illness
onset to hospital admission, fever, and corticosteroid use were associated with delayed clearance of viral
RNA. None of the antiviral regimens (chloroquine, oseltamivir, arbidol, and lopinavir/ritonavir) improved
viral RNA clearance. Lopinavir/ritonavir was associated with delayed clearance of viral RNA after adjusting
for confounders.

•

Neither lopinavir/ritonavir or arbidol provided virologic or clinical benefit in an RCT
In a randomized controlled trial (partially blinded) 34 patients with mild/moderate disease were assigned to
LPV/r, 35 to arbidol and 17 had no antiviral medication. There were no significant differences in duration of
viral shedding, rates of symptoms resolution or improvement of chest CT, or rates of progression to severe
states.

•

The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
The authors evaluated six currently available and licensed anti-influenza drugs against SARS-CoV-2 in vitro:
arbidol, baloxavir, laninamivir, oseltamivir, peramivir, and zanamivir. Among the six drugs, only arbidol
efficiently inhibited SARS-CoV-2 infection. Functionally, it appears to block virus entry by impeding viral
attachment and release from the endolysosomes. Although the selectivity index (SI) of arbidol is relatively
low (SI=7.73), as a repurposed drug, its pharmacokinetics profile such as maximal concentration (Cmax) is
more important for predicting efficacy.

Azithromycin
•

Hypothesis: azithromycin reduces viral invasion, including lung stem cells
SARS-CoV-2 invades host cells via two receptors: angiotensin-converting enzyme 2 (ACE2) and CD147 (also
known as Basigin or EMMPRIN). Hypothesis is that azithromycin could block cell invasion through its impact
on these receptors, could reduce invasion of lung stem cells that express ACE2, and be key in repair and
recovery.

•

Chart review showed ECG QT prolongation in HCQ +azithromycin (no control group)
The charts were reviewed in 84 patients receiving HY and AZ for 5 days. QT prolongation was observed
from a baseline average of 435 ± 24 ms to a maximal average of 463 ± 32 ms (P< 0.001 (one-sample t-test),
which occurred on day 3.6 ± 1.6. In a subset of nine (11%) of those patients, the QTc was severely
prolonged to >500 ms, a known marker of high risk of malignant arrhythmia and sudden cardiac death.

•

NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19
NIH will start a Phase 2b placebo-controlled trial enrolling 2,000 symptomatic adults with confirmed COVD19 in US to assess whether hydroxychloroquine and azithromycin can prevent hospitalization and death
and to assess its safety and tolerability. Those over 60 with co-morbidities, pregnant/breastfeeding women,
and people living with HIV are eligible to participate.

•

Potential zinc benefit in non-randomized retrospective hydroxychloroquine+azithromycin
study
MedRxiv preprint of retrospective observational study, not peer-reviewed: Patients were categorized based
on their exposure to hydroxychloroquine+azithromycin alone (n=521) or with zinc sulfate (n=411) as
treatment in addition to standard supportive care. The two groups did not differ with respect to age, race,
sex, tobacco use or past medical history. After adjusting for zinc therapy timing, the authors found that
addition of zinc sulfate to hydroxychloroquine and azithromycin is associated with an increased frequency
of being discharged home (OR 1.53, 95% CI 1.12-2.09) and significant reduction in mortality or transfer to
hospice (OR 0.449, 95% CI 0.271-0.744).

•

QT interval increased in COVID-19 patients treated with hydroxychloroquine and
azithromycin
Nature Medicine Letter to Editor: Authors reviewed the charts and followed the corrected QT (QTc) interval
in a consecutive cohort of 84 patients. Hydroxychloroquine and azithromycin were administered orally for
5 days. There was a prolongation of the QTc from a baseline average of 435 ± 24 ms (mean ± s.d.) to a
maximal average value of 463 ± 32 ms (P< 0.001 (one-sample t-test)), which occurred on day 3.6 ± 1.6 of
therapy. In a subset of nine (11%) of those patients, the QTc was severely prolonged to >500 ms, a known
marker of high risk of malignant arrhythmia and sudden cardiac death. In this high-risk group, the QTc
increased from a baseline average of 447 ± 30 ms to 527 ± 17 ms (P< 0.01 (one-sample t-test)).

Baricitinib
•

NIH announces trial combining antiviral remdesivir and antiinflammatory drug baricitinib
The NIAID-sponsored trial is expected to open at approximately 100 U.S. and international sites and enroll
more than 1000 participants. Baricitinib, taken orally, inhibits cytokine signaling in the body that plays a
role in causing inflammatory responses. The putative benefit of baricitinib for COVID-19 has been described
in a case series of critically ill patients who recovered. The combination of remdesivir and baricitinib has not
been evaluated in a large, randomized controlled treatment trial. One arrm will receive baricitinib tablets
orally and intravenous (IV) remdesivir, and the other will receive placebo tablets orally and IV remdesivir in
this double-blind study. The primary outcome is time to recovery, with secondary outcomes examining
severity and mortality.

Bexarotene
•

Bexarotene, Cetilistat, Diiodohydroxyquinoline, and Abiraterone as potential treatments
Pharmacological Research: The authors established a two-tier drug screening system that combines SARSCoV-2 enzyme-linked immunosorbent assay and cell viability assay and applied it to screen a library
consisting 1528 FDA-approved drugs. Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (antiparasitic), abiraterone acetate (synthetic androstane steroid), and bexarotene (antineoplastic retinoid)
exhibited potent in vitro anti-SARS-CoV-2 activity (EC50 1.13-2.01microM). Bexarotene demonstrated the
highest Cmax:EC50 ratio (1.69) which was higher than those of chloroquine, hydroxychloroquine, and
ivermectin. Thus, two-tier screening system is effective and identified potential COVID-19 treatments which
can achieve effective levels if given by inhalation or systemically depending on their pharmacokinetics.

Calcium channel blockers
•

Calcium channel blocker amlodipine is associated with reduced case fatality
Madrid preprint: 4 calcium channel blocker (CCB) antihypertensives showed in vitro inhibition of viral
replication. In this retrospective study of hospitalized hypertensive patients (n=90) with 15 fatalities,
amlodipine besylate (Norvasc) was compared to no treatment and other antihypertensives. Case fatality
rate (CFR) was decreased from 26.1% (12/46) in non-amlodipine treated group to 6.8% (3/44) in
amlodipine treated group (P = 0.022). Kaplan-Meier analysis demonstrated reduced risk of death in
amlodipine group, in comparison with non-amlodipine one (P = 0.033, log-rank test). Other CCBs (n=4) did
not have enough sample size for comparison. In vitro studies also suggest synergism of chloroquine and
CCBs.

Camostat mesylate
•

Danish trial begins for a pancreatic drug camostat mesylate to treat COVID-19
The drug is already licensed in Japan and South Korea to treat pancreatitis. The trials began on April 3rd
2020.

Cepharantine
•

Cepharantine is a potent in vivo inhibitor of the pangolin SARS-CoV-2-related infection
model
The SARS-CoV-2 related pangolin coronavirus GX_P2V/pangolin/2017/ Guangxi model was used to screen
compounds, by first screening 2406 clinical drugs in vitro (Vero E6 cells, GX_P2X virus). Viral yields of RNAs
and infectious particles were quantified with qRT-PCR. Cepharanthine (CEP), selamectin and mefloquine
completely inhibited cytopathic effects in cell culture at 10 μM. CEP was the most potent inhibitor of the
pangolin GX_P2V infection (EC50 = 0.98 μM). CEP is a natural product drug, approved in Japan to treat a
variety of conditions, including malaria, “without major side effects”.

Cetilistat
•

Bexarotene, Cetilistat, Diiodohydroxyquinoline, and Abiraterone as potential treatments
Pharmacological Research: The authors established a two-tier drug screening system that combines SARSCoV-2 enzyme-linked immunosorbent assay and cell viability assay and applied it to screen a library
consisting 1528 FDA-approved drugs. Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (antiparasitic), abiraterone acetate (synthetic androstane steroid), and bexarotene (antineoplastic retinoid)
exhibited potent in vitro anti-SARS-CoV-2 activity (EC50 1.13-2.01microM). Bexarotene demonstrated the
highest Cmax:EC50 ratio (1.69) which was higher than those of chloroquine, hydroxychloroquine, and
ivermectin. Thus, two-tier screening system is effective and identified potential COVID-19 treatments which
can achieve effective levels if given by inhalation or systemically depending on their pharmacokinetics.

Chlorpromazine
•

Antipsychotic medication chlorpromazine inhibits replication of SARS-CoV-2
The antiviral activity of chlorpromazine (CPZ) is mainly associated to inhibition of clathrin-mediated
endocytosis (15–18), via translocation of clathrin and AP2 from the cell surface to intracellular endosomes.
This in vitro study of CPZ antiviral activity against SARS-CoV-2 in monkey and human cells supports the
repurposing of CPZ.

Clozapine
•

Experience of the US clozapine clinic in treating schizophrenia patients during the COVID19
Schizophrenia Research: Antipsychotic Clozapine is the only medication in the USA dispensed with a “no
blood, no drug” FDA mandate, requiring regular absolute neutrophil count (ANC) reporting. FDA issued
guidance that prescribers may use clinical judgment on whether the benefits of deferring laboratory
monitoring (ANC) outweighs the risk of continuing clozapine treatment without an updated ANC. The
authors permitted patients receiving clozapine for ≥1 year with normal ANCs and with no signs of infection
to switch to telepsychiatry nurse visits; at the discretion of the attending physician, monthly ANC
requirements were also relaxed up to every 3 months, consistent with a recent expert consensus
statement. Starting in early April through May15, 2020, fifty patients (27%) had ANC monitoring exempted.
At the time of writing (May 18, 2020), no clinical decompensation among clozapine treated patients has
occurred.

Corticosteroids
•

Corticosteroids show no retrospective benefit in severe or critical cases in Wuhan
Corticosteroid use showed no benefit in reducing in-hospital mortality for severe or critical cases in two
medical centers in Wuhan, China. Corticosteroids were administered in 35.1% of severe cases (531 out of
1514 total) and 63.9% (159 out of 249 total) of critical cases. Since this was not a randomized controlled
trial and patients with more severe disease were more likely to be given systemic corticosteroids, results
should be interpreted with caution.

•

Early short course of corticosteroids reduces symptom escalation in moderate, severe
patients
The study (n=213) used methylprednisolone to treat moderate and severe patients. The composite
endpoint of escalation of care and mortality occurred at a significantly lower rate in post-corticosteroid
group (n=132) compared to pre-corticosteroid group (n=81) (34.9% vs. 54.3%, p=0.005). The postcorticosteroid group showed a significant reduction in median time spent in the hospital (8 vs. 5 days, p <
0.001). Multivariate regression analysis demonstrated an independent reduction in the composite endpoint
at 14-days controlling for other factors (aOR: 0.45; 95% CI [0.25 – 0.81]).

•

Corticosteroids and SARS-CoV-2/SARS-CoV/MERS-CoV outcomes: a meta-analysis advises
caution
Corticosteroid use was associated with delayed virus clearing with a mean difference (MD) = 3.78 days
(95% confidence Interval [CI] = 1.16, 6.41 days; I(2) = 0%). There was no significant reduction in deaths with
relative Risk Ratio (RR) = 1.07 (90% CI = 0.81; 1.42; I(2) = 80%). Hospitalization duration was prolonged and
use of mechanical ventilation increased.

•

Adjuvant corticosteroid therapy for critically ill patients with COVID-19
The data on 244 patients with COVID-19 who had complete records and were critically ill and treated with
antiviral agents were enrolled. All patients were given antiviral therapy and 151 patients (62%) were given
adjuvant corticosteroid treatment. Multivariate analysis adjusted for major mortality-associated variables
and propensity score and indicated that corticosteroid treatment was independent from overall mortality
at 28 days after admission (adjusted OR 1.05) The addition of adjuvant corticosteroid therapy was not
associated with28-day mortality. However, increased corticosteroid dosage was significantly associated
with elevated mortality risk after adjustment for administration duration; every 10-mgincrease in dosage
was associated with an additional 4% mortality risk.

Dexamethasone
•

Demand for dexamethasone surges as RECOVERY trial releases preprint to some criticism
The BMJ reporting on medRxiv preprint: Production of dexamethasone must be rapidly ramped up to meet
global demand for the drug, the WHO has said. The call came as the University of Oxford’s RECOVERY trial
published its much-anticipated preprint paper on the drug’s effect on covid-19. The paper preprint states
that the drug cuts deaths in ventilated patients by one third and deaths in other admitted patients
receiving oxygen by only one fifth. John Fletcher, research editor at The BMJ who screened the preprint for
MedRxiv, said that the trial was useful but that there were “limitations and cause for caution”. He said, “the
authors have used relative reductions and chosen the subgroup with the biggest benefit to generate a
headline of a one third reduction in deaths. The subgroup analysis was not specified in the trial registry and
may be misleading.” Fletcher also noted that the final outcome was unknown for at least 28% of people
entered in the trial, as 1807 were still in hospital at 28 days, the endpoint of the trial.

•

Dexamethasone, a drug recently shown to reduce coronavirus death risk could run out,
experts warn
Science: Issues of hoarding, manufacturing capacity, and a history of quality problems from one of the two
major suppliers of the drug raise questions about whether the drug will be available in needed quantities to
treat severe COVID-19 cases. The sickest patients are the ones most likely to benefit from the drug. In the
RECOVERY clinical trial, dexamethasone reduced the death risk for patients on a ventilator by one-third,
and for those requiring oxygen by one-fifth. Patients with milder disease did not benefit.

•

Further details on the UK RECOVERY dexamethasone trial
Oxford University press release: While the results on the UK RECOVERY trial on the steroid dexamethasone
are yet to be published, it was halted by the Steering Committee because sufficient patients had been
enrolled to establish benefit. The trial web site reported on the effect sizes and their statistical significance.
Dexamethasone (6 mg/d for 10 days) reduced deaths by one-third in ventilated patients (rate ratio 0.65
[95% confidence interval 0.48 to 0.88]; p=0.0003) and by one fifth in other patients receiving oxygen only
(0.80 [0.67 to 0.96]; p=0.0021). There was no benefit among those patients who did not require respiratory
support (1.22 [0.86 to 1.75]; p=0.14).

•

UK RECOVERY trial finds steroid dexamethasone reduces mortality by 1/3 in severe
COVID-19 cases
The UK National Institute of Health Research reports in a press release that their RECOVERY trial of
dexamethasone shows improved survival rates for ventilated patients with COVID-19 over usual care. A
total of 2104 patients were randomized to dexamethasone once per day for ten days and were compared
with 4321 patients randomized to usual care alone. Among the usual care control group, 28-day mortality
was highest in those on ventilators (41%), intermediate in those on oxygen only (25%), and lowest among
those who were not receiving any respiratory intervention (13%). Overall, dexamethasone reduced the risk
of 28-day mortality by 17% with a highly significant trend showing greatest benefit among those on
ventilators. Mortality was reduced by 1/3 in ventilated patients and by 1/5 in patients receiving oxygen
only. No evidence of benefit was found for patients who did not receive oxygen and the study did not
include patients outside the hospital setting. Follow-up is complete for over 90% of participants. The trial
results are not yet published in a peer-reviewed manuscript.

ECMO therapy
•

COVID-19 case successfully treated using extracorporeal membrane oxygenation (ECMO)
In this case report early ECMO dramatically helped recovery of severely ill patient.

and restoring normal physiological mechanisms with no evident toxic and side effects.

•

Extracorporeal membrane oxygenation for respiratory failure in COVID-19 patients
Canadian Journal of Anesthesia: In a prospective case series study the data were collected on 12 COVID-19
patients admitted for ECMO therapy continuing for 12 days. 67% of patients were discharged from the ICU
and 33% died. All patients were treated with inhaled nitric oxide, neuromuscular blockade, and prone
positioning prior to ECMO therapy. All patients received heparin treatment. Common complications of
disease in ECMO patients included acute kidney injury (92%), thrombosis (92%), and ventilator associated
pneumonia (83%). For patients weaned from ECMO, biological data showed an increase in lymphocyte
count (from 560 mm-3 to 1,280 mm-3) and a decrease in fibrinogen (from 6.8 gL-1to 3.6 gL-1). There was
an increase in PaO2/FIO2 ratio from 129 mmHg to 268 mmHg, and an initial decrease in respiratory
compliance from 29.3 to19.3 mLmmHg-1, followed by an increase to 26.8 mLmmHg-1.

Erythropoetin
•

Case report of recombinant human Erythropoietin administration saving 80-yo critically ill
male
Patient was given antiviral treatments, blood transfusion, plus 4000 IU recombinant human
Erythropoietin(rhEPO) due to his severe anemia. Anemia and lymphocytopenia resolved quickly, and he
recovered in 7 days.

Famotidine
•

Famotidine associated with improved clinical outcome
Pre-proof: In a retrospective cohort study (n=1,620), famotidine use (n=84) within 24 hours of admission
was associated with reduced intubation or death. Authors highlighted that this association cannot be used
to claim that the medication is protective. A follow-up RCT is currently underway.

Farxiga
•

AstraZeneca tests dapagliflozin (Farxiga) as possible COVID-19 treatment
AstraZeneca and Saint Luke's Mid American Heart Institute have started a randomized, global Phase III
clinical trial to assess dapagliflozin (an SGLT2 inhibitor used for Type II Diabetes) as a way to reduce disease
progression, clinical complications, and death in hospitalized COVID-19 patients with cardiovascular,
metabolic, or kidney risk factors. Dapagliflozin has previously been shown to have cardio and renal
protective benefits.

Favipiravir
•

Influenza antiviral Avigan® (favipiravir) to enter Phase III trials in COVID-19 patients
FUJIFILM Toyama Chemical Co. Ltd. is starting a Phase III trial to evaluate the safety and efficacy of its antiinfluenza drug, Avigan® (favipiravir) for patients of COVID-19. Avigan, approved in Japan as an influenza
antiviral, selectively inhibits the RNA polymerase of the influenza virus. Since SARS-CoV-2 uses the same
type of enzyme to replicate and is classified into the same type of single-stranded RNA viruses as influenza,
it is believed that Avigan will be effective in treating COVID-19.

•

Experimental treatment with favipiravir for COVID-19: an open-label control study
Patients treated with favipiravir were compared with historical controls. A shorter viral clearance time was
found for the FPV arm versus historical controls, 4 (2.5-9) d versus 11 (8-13) d, P < 0.001). The FPV arm also

showed significant improvement in chest imaging compared with historical controls with an improvement
rate of 91.43% versus 62.22% (P = 0.004). The study design and high ED50 for favipiravir raise questions
about the validity of this report.

Fibrinolytic therapy
•

Potential treatment of COVID-19 using Tissue Plasminogen Activator (tPA)
Severe COVID-19 is characterized with coagulopathy. 71.4% of mortalities due to COVID-19 meet ISTH
criteria for disseminated intravascular coagulation, with only 0.6% survivors meeting these criteria.
Evidence in both animal models and humans suggest that fibrinolytic therapy in acute lung injury and ARDS
improves survival.

•

Pre-terminal state gas exchange abnormalities may be responsive to thrombolysis
therapy
Researchers reported that four patients with refractory respiratory failure requiring mechanical ventilation
and shock with evidence of elevated dead-space ventilation showed improvement when given systemic
tPA. Patients given Heparin + tPA because of increased risk of VTE and elevated D-dimer experienced
improved alveolar ventilation and oxygenation.

Heparin
•

The association between treatment with heparin and survival in patients with Covid-19
Journal of Thrombosis and Thrombolysis: In a prospective study, clinical data were collected from the 2075
patients with Covid-19, admitted in 17 hospitals in Spain. Heparin had been used in 1734 patients and was
associated with lower mortality when the model was adjusted for age and gender, with OR (95% CI) 0.55
(0.37-0.82) p = 0.003. This association remained significant when saturation of oxygen < 90%, and
temperature > 37 degrees C were added to de model with OR 0.54 (0.36-0.82) p = 0.003, and also when all
the other drugs were included as covariates OR 0.42 (0.26-0.66) p < 0.001.

Hydroxychloroquine and chloroquine
•

Hydroxychloroquine versus COVID-19: a rapid systematic review and meta-analysis
A medRxiv preprint: Seven studies including four clinical trials and three observational studies have entered
into the study. The results of meta-analysis of three clinical trial studies (128 patients) showed that there
were no significant differences between patients who received the standard treatment with HCQ regimen
and the patients that received the standard treatment without HCQ (RR: 1.44, 95% CI, 0.80-2.59). Among
the individual clinical trials, two studies reported a benefit and another did not.

•

Prevention and treatment of QT prolongation with hydroxychloroquine and azithromycin
This letter responds to hydroxychloroquine and azithromycin use and its increase risk for torsades de
pointes through QT prolongation. The author urges physicians to monitor patients being treated with these
drugs through baseline EKG with continuous monitoring, limiting polypharmacy especially drugs known to
prolong QT interval and supplemental potassium. In the event of torsades, the author recommends
discontinuation of offending drug, IV magnesium and/or isoproterenol.

•

No evidence of rapid antiviral clearance or clinical benefit with
hydroxychloroquine/azithromycin
Negative study: 8 out of 10 patients tested positive for SARS-CoV-2 after 6 days of treatment with the
combination hydroxychloroquine/azithromycin. This is contrary to the earlier “rapid viral clearance” report
based on 6 patients.

•

CDC no longer recommends hydroxychloroquine as potential treatment for coronavirus
Following major concerns regarding the validity of the Gautret et al initial study, the CDC revised its
guidance regarding treatment options for SARS-CoV-2. The CDC no longer states that chloroquine and
hydroxychloroquine are "reportedly well-tolerated in COVID-19 patients." Instead, it states "There are no
drugs or other therapeutics approved by the U.S. Food and Drug Administration to prevent or treat COVID19."

•

New hydroxychloroquine dosing recommendations to minimize time to therapeutic dose
Given its variable pharmacokinetic properties, there can be delays in achieving optimal target blood levels
of HCQ. A modified dosing strategy is proposed. Blood HCQ trough levels between 1 and 2 mg/L are
considered therapeutic. Only 8/13 patients achieved minimal level using 3x/day 200mg dose; 2 patients
exceeded the maximum dose. Mean time to therapeutic dose was 2.7 days. Recommendation for ICU
patients: Single 800 mg loading dose Day 1, followed by 200 mg 2x/day for 7 days.

•

Avoid hydroxychloroquine + azithromycin for patients with QT interval prolongation:
AHA, ACC, HRS
The American Heart Association, American College of Cardiology, and Heart Rhythm Society recommend
that the combination of hydroxychloroquine and azithromycin be withheld in patients with baseline QT
ECG prolongation.

•

Hydroxychloroquine is safe alone. With azithromycin: 2.19-fold higher 30-day
cardiovascular mortality
UNM participates in the largest observational study to date on HCQ safety. Global OHDSI consortium used
956,374 and 310,350 users of HCQ and sulfasalazine respectively, as well as 323,122 and 351,956 users of
HCQ+azithromycin and HCQ+amoxicillin respectively, all with rheumatoid arthritis. Meta-analyses were
done on studies performed over a global data network for 16 adverse events in both 30-day follow-up and
self-controlled case series (SCCS) designs. No excess risk for any of the 16 adverse events was identified
when 30-day HCQ and sulfasalazine use were compared. SCCS confirmed these findings.
Azithromycin+HCQ had increased risk of 30-day cardiovascular mortality (HR=2.19, 95% CI: (1.22-3.94)),
chest pain/angina HR=1.15 (1.05-1.26), and heart failure 1.22 (1.02-1.45), over azithromycin-amoxicillin.
Paper under peer review.

•

No drug should be assumed to be efficacious: Oxford review on Chloroquine and HCQ
No intervention should be assumed to be efficacious for COVID-19. Even drugs initially supported by
evidence of effectiveness may later prove to be more harmful than beneficial. Too many medicines have
been withdrawn because of adverse reactions after showing clinical promise. We need better, properly
powered, randomized controlled trials of chloroquine or hydroxychloroquine. For now, except for
supportive measures, infection with SARS-CoV-2 is “essentially untreatable.”

•

Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19
patients
Risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from
the Indian Heart Rhythm Society. This includes a brief review of cardiovascular effects, with respect to its
propensity to cause QT interval prolongation and potentially lethal cardiac arrhythmia in certain patients.

•

Chinese multi-center hydroxychloroquine RCT shows no efficacy in reduction of viral load
Awaiting peer-review. This 150-patient 16-center open-label, randomized, controlled trial fails to show
significance for its primary endpoint of 28-day negative conversion rate of SARS-CoV-2, as well as
secondary endpoints at days 4, 7, 10, 14, or 21. Treatments were HCQ with/without standard of care (SOC).
HCQ dosing: 1,200 mg/day for Days 1-3, followed by 800 mg/day for the remaining days (14 for moderate,

21 for severe patients). A significant efficacy of HCQ on alleviating symptoms was observed when the
confounding effects of anti-viral agents were removed in the post-hoc analysis (Hazard ratio, 8.83, 95%CI,
1.09 to 71.3). This was further supported by a significantly greater reduction of CRP (6.986 in SOC plus HCQ
versus 2.723 in SOC, milligram/liter, P=0.045) conferred by the addition of HCQ, which also led to more
rapid recovery of lymphopenia, albeit no statistical significance. Adverse events (AEs) were found in 8.8% of
SOC and 30% of HCQ recipients with two serious adverse events. The most common AE in the HCQ
recipients was diarrhea (10%). Mean day from disease onset to randomization was 16.6 and 89% of the
patients had concomitant medication before randomization.

•

No evidence of clinical efficacy of HCQ in COVID-19 pneumonia patients with oxygen
therapy
Data from French hospitals on adults with SARS-CoV-2 pneumonia (N = 181). 84 patients received HCQ
within 48 hours of admission; 97 did not. Initial severity was balanced between the groups. In the "HCQ”
group, 20.2% were transferred to ICU or died within 7 days, vs. 22.1% in the "no-HCQ group" (16 vs 21
events, relative risk [RR] 0.91, 95% CI 0.47-1.80, weighted analysis). 2.8% of the "HCQ" patients died within
7 days vs 4.6% in the no-HCQ group (3 vs 4 events, RR 0.61, 95% CI 0.13-2.89), and 27.4% and 24.1%,
respectively, developed acute respiratory distress syndrome within 7 days (24 vs 23 events, RR 1.14, 95% CI
0.65-2.00). Eight patients receiving HCQ (9.5%) experienced electrocardiogram modifications requiring
HCQ discontinuation. These results do not support the use of HCQ in patients hospitalized for documented
SARS-CoV-2-positive hypoxic pneumonia.

•

Antivirals do not reduce time of viral clearance, lopinavir/ritonavir delayed viral clearance
MedRxiv preprint: Guangzhou study examined 284 consecutive COVID-19 cases. 280 patients achieved viral
RNA clearance with a median length of 12 days (IQR: 8-16) after onset of illness. 66.1% of them had viral
RNA cleared within 14 days, and 89.3% within 21 days. Older age, severity of disease, time lag from illness
onset to hospital admission, fever, and corticosteroid use were associated with delayed clearance of viral
RNA. None of the antiviral regimens (chloroquine, oseltamivir, arbidol, and lopinavir/ritonavir) improved
viral RNA clearance. Lopinavir/ritonavir was associated with delayed clearance of viral RNA after adjusting
for confounders.

•

Age-adjusted pediatric chloroquine dose: modeling/simulation-based recommendations
A physiologically based pharmacokinetic (PBPK) model for CHQ was used to simulate exposure in adults
and children and verified against published PK data. The authors propose the following total cumulative
doses: 35 mg/kg (CHQ base) for children 0-1 month, 47 mg/kg for 1-6 months, 55 mg/kg for 6 months-12
years and 44 mg/kg for adolescents and adults, not to exceed 3300 mg in any patient.

•

Increased numbers in hydroxychloroquine clinical trials following politicians' comments
Nature News: Researchers in multiple countries report that participants are choosing to enroll in clinical
trials for hydroxychloroquine over other clinical trials. They believe this is in response to the optimistic
comments politicians have made about the drug, despite the "insufficient data to recommend either for or
against the use of chloroquine and hydroxychloroquine in people with COVID-19."

•

FDA cautions against hydroxychloroquine and chloroquine use outside the hospital or
clinical trials
The FDA stated that abnormal heart rhythms and rapid heart rate risks may increase when the medicines
are combined with other drugs, such as antibiotic azithromycin, as well as in patients with existing heart
and kidney disease. FDA cautioned that careful monitoring is strongly recommended and that use should
be limited to clinical trials and inpatient treatment.

•

Higher chloroquine dose associated with higher mortality: RCT results
In this phase IIb trial of 81 COVID19 patients in Brazil randomized to high vs low-dose chloroquine (CQ). The
higher dose was associated with higher mortality (39% vs 15%) and QTc interval prolongation (18.9% vs
11.1%)

•

Hydroxychloroquine caused severe haemolysis crisis in patient with G6PD deficiency
G6PD is the most common enzyme deficiency in humans with 400M cases worldwide. It has known risk for
haemolytic crisis when patients is exposed to oxidative agents (fava beans, drugs, infections),
hydroxychloroquine being a suspected trigger. Case report shows first case of severe haemolytic crisis in a
patient with G6PD deficiency, initiated by severe COVID-19 infection and hydroxychloroquine use.

•

Hazards of high adjunctive chloroquine dose for patients with SARS-CoV-2: RCT
This parallel, double-blinded, randomized, phase IIb clinical trial enrolled 81 adult inpatients with SARSCoV-2 ((41 [50.6%] to the high-dosage group and 40 [49.4%] to the low-dosage one). The preliminary
findings of this study suggest that the higher CQ dosage should not be recommended for critically ill
patients with COVID-19 because of its potential safety hazards, especially when taken concurrently with
azithromycin and/or oseltamivir.

•

Meta-analysis of hydroxychloroquine placebo randomized controlled trials fails to show
benefit
MedRxiv preprint: Meta-analysis included 11 RCTs with 2613 adult patients from studies on hepatitis,
chikungunya, HIV, dengue, influenza, and COVID-19 (one study). Both the plasma viral load (standard mean
difference: 0.29, 95% CI: -1.19-1.76, P = 0.70) and the improvement of clinical symptoms (odds ratio: 2.36,
95% CI: 0.81 - 6.92, P = 0.11) were not statistically significantly different between the intervention and
placebo arm. Insufficient data were available to support the antiviral efficacy of CQ and HCQ due to the
high heterogeneity caused by the age of patients. Mild side effects are expected for the current antiviral
dose regimens of CQ and HCQ (Risk Ratio 1.51, 95% CI: 1.35 -1.70, P<0.05). Treatment outcomes may be
enhanced by better-selected patients based on age and well-controlled adverse events.

•

Post-exposure prophylaxis for COVID-19 with hydroxychloroquine
In one Korean long-term care hospital, post-exposure prophylaxis (PEP) with HCQ was done in 189 patients
and 22 healthcare workers (HCWs) who were COVID-19-negative by PCR. PEP was completed in 184
(97.4%) patients and 21 (95.5%) HCWs without serious adverse events. At the end of 14 days of quarantine,
follow-up PCR tests were all negative. There were no untreated controls.

•

No evidence of clinical benefit from hydroxychloroquine therapy in a retrospective
analysis in US veterans hospitalized with COVID-19
MedRxiv preprint: In this non peer-reviewed, retrospective study, 97 COVID-19 patients were treated with
hydroxychloroquine (HCQ), 113 were treated with HCQ and azithromycin (AZ) and 158 did not receive HCQ.
HCQ with or without AZ did not reduce risk of ventilation, and there was an association with increased
overall mortality in patients treated with HCQ alone after adjustment for initial clinical characteristics via
propensity scores.

•

Aerosolized hydroxychloroquine to treat COVID-19
The authors propose the use of aerosolized HCQ (2-4 mg per inhalation) in order to reach therapeutic
levels at alveolar epithelial cells. Data on self-medication for one week by two of the authors is presented.

•

Hydroxychloroquine and chloroquine safety issues
A multinational registry analysis showed that after controlling for multiple confounding factors, when
compared with mortality in the control group (9.3%), hydroxychloroquine (18.0%; hazard ratio 1.335, 95%
CI 1.223-1.457), hydroxychloroquine with a macrolide (23.8%; hazard ratio 1.447, 1.368-1.531),

chloroquine (16.4%; hazard ratio 1.365, 1.218-1.531), and chloroquine with a macrolide (22.2%; hazard
ratio 1.368, 1.273-1.469) were each independently associated with an increased risk of in-hospital
mortality. Risk of de-novo ventricular arrhythmia during hospitalization increased compared with the
control group (0.3%), hydroxychloroquine (6.1%; hazard ratio 2.369, 1.935-2.900), hydroxychloroquine with
a macrolide (8.1%; hazard ratio 5.106, 4.106-5.983), chloroquine (4.3%; hazard ratio 3.561, 2.760-4.596),
and chloroquine with a macrolide (6.5%; hazard ratio 4.011, 3.344-4.812).

•

An independent appraisal and re-analysis of HCQ treatment trial for COVID-19
Reanalysis of HCQ trials were reviewed. It was concluded that HCQ-treated groups approached significantly
increased cure rates on day 6 (n = 6), demonstrating promising pilot data. HCQ has not yet demonstrated
significant effects on decreasing viral load of SARS-CoV-2 (n = 15). Additional trials with larger sample sizes
and more consistent analysis of patient data are needed.

•

Hydroxychloroquine treatment results in slower viral clearance
In an underpowered, retrospective trial with risk of selection bias, patients with mild to moderate disease
treated with hydroxychloroquine showed longer time to clear the virus than patients that were not treated
with HCQ.

•

Hydroxychloroquine & QT prolongation in COVID-19
Two recent studies in JAMA Cardiology provided additional evidence that hydroxychloroquine treatment is
associated with prolonged QTc interval in COVID-19. In the first study, 10 of 90 patients had
hydroxychloroquine stopped early for adverse events, including one patient who developed torsades de
pointes (doi.org/doi:10.1001/jamacardio.2020.1834). In the second study, 1/3 of those on
hydroxychloroquine and azithromycin developed QTc of 500 ms or more, versus 5% on hydroxychloroquine
alone (doi.org/doi:10.1001/jamacardio.2020.1787). An accompanying editorial discussed concerns raised
by the two studies and the previously reported Brazilian study by Borba.

•

NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19
NIH will start a Phase 2b placebo-controlled trial enrolling 2,000 symptomatic adults with confirmed COVD19 in US to assess whether hydroxychloroquine and azithromycin can prevent hospitalization and death
and to assess its safety and tolerability. Those over 60 with co-morbidities, pregnant/breastfeeding women,
and people living with HIV are eligible to participate.

•

Observational study of hydroxychloroquine in hospitalized patients: no support for use
outside RCTs
This NEJM article describing 1446 consecutive patients hospitalized at a hospital in New York City. After 70
who were intubated, died or transferred within 24 hours were excluded, 811 received hydroxychloroquine
and 565 did not. Patients who received hydroxychloroquine were more likely reach an endpoint of
intubation or death (HR 2.37, 95% CI 1.84-3.02), but outcomes were similar after matching for severity by
propensity score (HR 1.04, 95% CI 0.82 to 1.32). They conclude that the risk of intubation or death was not
significantly higher or lower among patients who received HCQ, but that their results do not support
hydroxychloroquine use outside of randomized clinical trials.

•

Avoid hydroxychloroquine in COVID-19-infected patients with schizophrenia
HCQ is known to cause a spectrum of psychiatric adverse effects. Treating physician should collaborate
with the treating psychiatrist to closely monitor for any exacerbations in psychiatric symptoms and should
minimize cardiac risk by switching antipsychotic medication with a high risk of QTc prolongation to a safer
agent.

•

No association between hydroxychloroquine use and intubation or death
NEJM: This is an observational study of 1376 patients, approximately half of whom received
hydroxychloroquine. Patients were matched via a propensity scoring system for multiple known risk

factors, initial status, and other treatments patient received. The authors of this observational study report
no significant association between hydroxychloroquine use and intubation or death with hazard ratio 1.04
(95% CI: 0.82-1.32). The authors acknowledge the need for randomized control trials using
hydroxychloroquine.

•

Use of chloroquine and potential adverse outcomes in G6PD deficient patients
Based on studies done on the hemolytic effect of chloroquine use in G6PD deficient individuals, caution
should be taken in using it in treatment of patients unaware of their deficiency status yet infected with the
virus. Chloroquine and the potential adverse outcome in undiagnosed G6PD-deficient cases infected with
COVID-19.

•

Highest number of clinical trials being conducted on hydroxychloroquine, followed by
remdemsivir
A systematic review of clinical drug trials showed that by the end of June we will have results of almost 20
trials involving 40000 patients for hydroxychloroquine and 5 trials with 4500 patients for remdesivir;
however, low statistical power is expected from the 9 clinical trials testing the efficacy of favipiravir or the 5
testing tocilizumab, since each one will recruit less than 1000 patients.

•

S-Hydroxychloroquine as a potentially superior drug compared to R-HCQ
Preprint: The clinical outcome from previous CQ or HCQ trials were the collective manifestation of both R
and S enantiomers with inherent different pharmacodynamic, pharmacokinetic properties, and toxicity
liabilities. S-chloroquine (S-CQ) and S-hydroxychloroquine (S-HCQ) were found to be 27% and 60% more
active against SARS-CoV-2, as compared to R-CQ and R-HCQ, respectively.

•

Potential zinc benefit in non-randomized retrospective hydroxychloroquine+azithromycin
study
MedRxiv preprint of retrospective observational study, not peer-reviewed: Patients were categorized based
on their exposure to hydroxychloroquine+azithromycin alone (n=521) or with zinc sulfate (n=411) as
treatment in addition to standard supportive care. The two groups did not differ with respect to age, race,
sex, tobacco use or past medical history. After adjusting for zinc therapy timing, the authors found that
addition of zinc sulfate to hydroxychloroquine and azithromycin is associated with an increased frequency
of being discharged home (OR 1.53, 95% CI 1.12-2.09) and significant reduction in mortality or transfer to
hospice (OR 0.449, 95% CI 0.271-0.744).

•

Small, open-label RCT finds no benefit to hydroxychloroquine use
Researchers from China report in the British Medical Journal an open-label RCT of 150 mainly mildmoderate patients that found no statistically significant benefit for hydroxychloroquine (HCQ) on viral
clearance at 28 days. 30% of patients in the HCQ group had adverse events vs 9% in the control group. No
serious adverse events were reported. The authors note that the study had 150 out of the 300 patients
they planned to recruit.

•

Use of hydroxychloroquine and azithromycin in outpatients associated with low mortality
A team led by the original French proponent of the hydroxychloroquine/azithromycin therapy issued a
retrospective report without a control arm or comparison population on 1,061 COVID-19 outpatients with
and without symptoms in France treated with hydroxychloroquine (HCQ) and azithromycin (AZ). The report
found good clinical outcome and cure in 973 patients (91%), poor clinical outcome in 46 (4.3%) and 8
deaths (0.75%). A total of 2.3% of patients reported mild adverse events. The authors claim that
administration of HCQ+AZ before COVID complications occur is safe and associated with very low fatality
rate.

•

Lysosomal storage disease might bring new insights on SARS-CoV-2

The authors propose that the lysosomotropic effects of HCQ and several other drugs may be responsible
for their in vitro antiviral activities against COVID-19. Pharmacological interventions targeting lysosomal
function constitute plausible mechanisms that could be used to target COVID-19.

•

Hydroxychloroquine or chloroquine +/- macrolide does not confer benefit and increases
frequency of ventricular arrhythmia
A multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a
macrolide was unable to confirm a benefit when used for treatment of COVID-19. Each of these drug
regimens was associated with decreased in-hospital survival and increased frequency of ventricular
arrhythmias.

•

Pausing of the HCQ arm of the Solidarity Trial with Dr. Tedros.
Video briefing covering WHO temporarily halting HCQ trial over safety concerns.

•

Hydroxychloroquine did not prevent illness compatible with COVID-19 in a double-blind
RCT
NEJM: A randomized, double-blind, placebo-controlled trial tested HCQ as postexposure prophylaxis. They
enrolled adults with a high- or moderate-risk exposure to SARSCoV2. Within 4 days after exposure, the
authors randomly assigned participants to receive either placebo or HCQ (N=821 asymptomatic
participants). 87.6% reported a high-risk exposure to a confirmed Covid-19 contact. The incidence of new
illness compatible with Covid-19 did not differ significantly between participants receiving HCQ (11.8% and
those receiving placebo 14.3%; the absolute difference was −2.4 percentage points (95% confidence
interval, −7.0 to 2.2; P=0.35). Side effects were more common with HCQ than with placebo (40.1% vs.
16.8%), but no serious adverse reactions were reported.

•

Study authors retract Lancet article suggesting no benefit of hydroxychloroquine for
COVID-19 patients
The Lancet: Following expressions of concern, authors retracted an influential article on
hydroxychloroquine originally published on May 22. The original article found there was no benefit of
treatment with chloroquine or hydroxychloroquine in hospitalized COVID-19 patients and raised concerns
regarding the risk/benefit ratio of these therapies outside of the treatment of autoimmune diseases.
However, the authors were not able to obtain an independent audit of the data underpinning these
conclusions, and the Lancet published their retraction of the article on June 4.
Here is the official retraction.

•

QT interval increased in COVID-19 patients treated with hydroxychloroquine and
azithromycin
Nature Medicine Letter to Editor: Authors reviewed the charts and followed the corrected QT (QTc) interval
in a consecutive cohort of 84 patients. Hydroxychloroquine and azithromycin were administered orally for
5 days. There was a prolongation of the QTc from a baseline average of 435 ± 24 ms (mean ± s.d.) to a
maximal average value of 463 ± 32 ms (P< 0.001 (one-sample t-test)), which occurred on day 3.6 ± 1.6 of
therapy. In a subset of nine (11%) of those patients, the QTc was severely prolonged to >500 ms, a known
marker of high risk of malignant arrhythmia and sudden cardiac death. In this high-risk group, the QTc
increased from a baseline average of 447 ± 30 ms to 527 ± 17 ms (P< 0.01 (one-sample t-test)).

•

Hydroxychloroquine toxicity: pharmacokinetics observational study
Intensive Care Medicine: Letter to the Editor. In this observational cohort study (n = 13) prescribing HCQ in
COVID-19 patients is unsafe for several reasons. Because of drug accumulation and high volume of
distribution, toxic threshold was reached by day 5 even in patients with normal renal function. The authors
recorded side effects although patients’ blood concentrations were in therapeutic range, therefore making

HCQ administration potentially harmful despite correct surveillance parameters. Hemodialysis had little
effect on HCQ concentrations, whereas the patient with veno-venous extracorporeal life support expressed
constant low HCQ blood concentration, possibly due to membrane adsorption. To avoid HCQ-related
complications in COVID-19 critically ill patients, the authors suggest monitoring EKG and blood
concentration daily.

•

Hydroxychloroquine not effective for COVID-19 prophylaxis
New England Journal of Medicine: In a double-blind, randomized trial, 821 asymptomatic persons with a
high-risk or moderate-risk exposure to SARS-CoV-2 were assigned to receive hydroxychloroquine or
placebo within 4 days after the exposure. No benefit in preventing illness compatible with Covid-19 was
found (P = 0.35).

Immunomodulators
•

Immune-suppressive and stimulating drugs and COVID-19: a systematic review of current
evidence
Cancer and transplant patients with COVID-19 have a higher risk of developing severe and even fatal
respiratory diseases, especially as they may be treated with immune-suppressive or immune-stimulating
drugs. This literature review shows that low-dose prednisolone and tacrolimus may have beneficial
impacts on COVID-19. The use of mycophenolate mofetil is less clear, with conflicting data from pre-clinical
studies. There is no definitive evidence that specific cytotoxic drugs, low-dose methotrexate for autoimmune disease, NSAIDs, JAK kinase inhibitors or anti-TNF alpha agents are contraindicated. There is clear
evidence that IL-6 peak levels are associated with the severity of pulmonary complications.

•

Withold dermatological immunomodulators for suspected/confirmed cases
Australia/New Zealand consensus statement. In patients with suspected or confirmed COVID-19 disease, all
immunomodulators used for skin diseases should be immediately withheld, with the possible exception of
systemic corticosteroid therapy, which needs to be weaned. In patients who develop symptoms or signs of
an upper respiratory tract infection, but COVID-19 is not yet confirmed, consider dose reduction or
temporarily cessation for 1-2 weeks. In otherwise well patients, immunomodulators and biologics should
be continued.

•

A viewpoint on the interferon lambda treatment option, pros and cons
This Viewpoint presents an opinion on the benefits and potential limitations of using IFN-lambda to
prevent, limit, and treat COVID-19.

•

Infection results in monocyte, macrophage, and dendritic cell activation
This perspective piece draws on experience with arthritis and cancer therapy. The resulting increased
systemic cytokine production contributes to the pathophysiology, including hypotension and acute
respiratory distress syndrome (ARDS). These might be treated with IL-6 antagonists such as tocilizumab,
sarilumab, and siltuximab.

•

Glucocorticoids reduce fever, but not lung inflammation or mortality in COVID-19
A meta-analysis of 23 studies was conducted looking at children and adults with COVID-19, Middle East
Respiratory Syndrome Coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome coronavirus (SARSCoV). In adults with COVID-19, the use of systemic glucocorticoid did not reduce mortality (RR=2.00, 95%
CI: 0.69 to 5.75) or the duration of lung inflammation (weighted mean differences , WMD=-1 days, 95% CI:
-2.91 to 0.91), while a significant reduction was found in the duration of fever (WMD=-3.23 days, 95% CI: 3.56 to -2.90). In patients with SARS, glucocorticoids also did not reduce the mortality (RR=1.52, 95% CI:
0.89 to 2.60, I2=84.6%), duration of fever (WMD=0.82 days, 95% CI: -2.88 to 4.52) or duration of lung

inflammation absorption (WMD=0.95 days, 95% CI: -7.57 to 9.48). Due to high rates of side effects,
glucocorticoids are not recommended by the authors for routine use in COVID-19 treatment.

•

Severe COVID-19 associated with deep and sustained multifaceted cellular
immunosuppression
Intensive Care Medicine: Letter to Editor. The authors present the first report on serial immunophenotypic
and functional changes in 13 consecutively recruited patients infected with SARS-CoV-2 virus during their
first week of ICU stay compared to 10 healthy controls. The results strongly suggest a multifaceted
devastating effect of the virus to cause depletion of virtually all classes of adaptive immune cells and to
cause upregulation of potent T cell killing and immunosuppressive mechanisms in critically ill COVID-19
patients. Since T cells are essential for definitive viral clearance, these results call into question therapies
(e.g., anti-IL-6, corticosteroids, JAK inhibitors) that aim to block the ability of the patient to mount an
effective immune response. Knowing that almost all anti-inflammatory therapies have also chronically
failed in sepsis, consideration to therapies that boost host immunity in selected severe ARDS ICU patients
(e.g., IL-7, IFN-γ or checkpoint inhibitors) may be appropriate

Immunotherapy
•

Mesenchymal Stem Cell Infusion Shows Promise for Coronavirus (COVID-19)- Induced
Pneumonia
Intravenous administration of clinical-grade human mesenchymal stem cells (MSCs) into seven patients
with COVID-19 resulted in improved functional outcomes and facilitated recovery.

•

Convalescent plasma therapy is effective in severe COVID-19 patients: initial findings
10 severe patients with COVID-19 were given one dose (200 mL) of convalescent plasma (CP) derived from
recently recovered donors as an addition to maximal supportive care and antivirals. Symptoms significantly
improved within 3 days. The viral load was undetectable after transfusion in 7 patients who had previous
viremia. CP therapy was well tolerated.

•

Immune (convalescent) plasma for the prevention and treatment of COVID-19
Limited data from China suggest clinical benefits, including radiological resolution, reduction in viral loads
and improved survival. A review of previous studies of viral infections suggest overwhelming benefits from
prophylaxis or treatment.

•

FDA Recommendations for Investigational COVID-19 Convalescent Plasma
FDA has issued guidance to health care providers and investigators on the administration and study of
investigational convalescent plasma collected from individuals who have recovered from COVID-19.

•

A systematic review of immunotherapy for COVID-19
The review shoed that although no serious research has been done on this subject at the time of writing
this article, similar studies on the related viruses showed notable results. Thus, immunotherapy for COVID19 can also be a suitable option.

•

Experimental treatment with convalescent plasma keeps running around the country
Doctors in Texas and around the country are experimenting with a new treatment based on an old
technique — but they aren’t sure if it will be effective.

•

Effect of regular intravenous immunoglobulin therapy on prognosis of COVID pneumonia
In this retrospective study, 58 cases were reviewed of severe or critical COVID-19 diagnosed in the
intensive care unit of Wuhan Third Hospital from January to February 2020. Initiation of IVIG as adjuvant
treatment for COVID-19 pneumonia within 48 hours of admission to the ICU was shown to statistically

significantly reduce the use of mechanical ventilation, shorten the hospital length of stay, promote the
early recovery of patients, and improve the effective treatment of patients to achieve significant clinical
efficacy.

•

FDA encourages recovered patients to donate plasma for development of blood-related
therapies
The FDA is providing an update on convalescent plasma and encouraging those who have recovered from
COVID-19 to donate plasma to help others fight this disease.

•

Convalescent plasma therapy is effective and specific for COVID-19
The efficacy of convalescent plasma therapy was assessed by the alleviation of symptoms, changes in
radiologic abnormalities and laboratory tests in a study of six patients. No obvious adverse effect observed
during the treatment. The authors conclude that convalescent plasma therapy is effective and specific for
COVID-19. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.

•

Tocilizumab - new therapeutic strategy for severe and critical cases
In a letter to the editor of the journal Travel Medicine and Infectious Disease, the author argues for the use
of tocilizumab as an IL-6-blocking treatment that may prevent the development of severe disease
outcomes.

•

Rationale for use of Tocilizumab in the treatment of coronavirus pneumonia
Clinical Drug Investigation: The authors discuss the role of cytokine storm in Covid-19; the mechanism of
Tocilizumab, an IL-6 receptor antagonist, in treatment; and key points of pharmaceutical case based on
clinical application. The role of Tocilizumab in treating the virus currently remains unclear.

•

Virus structure, immune response, hyperinflammation: review related to drug
repurposing
In this review, to better gain information about appropriate anti-inflammatory treatments, mostly used in
rheumatology for COVID-19, the authors have focused on the structural features of SARS-CoV-2, the host
immune response against SARS-CoV-2 and its association with the cytokine storm.

•

Case Series of Plasmapheresis treatment in Covid-19 related autoimmune
meningoencephalitis
Brain, Behavior, and Immunity: The authors report the results of plasmapheresis use in six ICU-admitted
patients with Covid-19 presenting with autoimmune meningoencephalitis. Four patients regained
consciousness and could be extubated after receiving one or several cycles of plasmapheresis, 1 patient
continued therapy due to reactivation of a CMV infection, and 1 patient worsened after one cycle of
therapy and died. Following therapy, improvements in serum ferritin levels were observed as well as
reversible MRI findings of meningoencephalitis.

•

Convalescent plasma safe in small study
Study aimed to evaluate the safety and potential benefit of convalescent plasma use in severely ill
hospitalized patients. There were no adverse events for the 25 patients receiving transfusion; 9/25
improved in seven days, and 19/25 improved in 14 days, assessed by ≥1 point improvement in a modified
clinical scale. Note that transfusion patients were also taking anti-virals and anti-inflammatory agents.

•

Examination of convalescent plasma effectiveness in past viral outbreaks
The authors reviewed the history of convalescent plasma use during previous viral outbreaks and
pandemics with particular focus on hemorrhagic fevers, influenza, and other coronaviruses.

•

Adjunctive convalescent plasma did not result in a shorter time to clinical improvement
JAMA: Open-label, multicenter, randomized clinical trial included 103 participants with severe/lifethreatening COVID-19 was terminated early after 103 of a planned 200 patients were enrolled. Clinical
improvement within 28 days was not significantly improved for the convalscent plasma group (51.9%
27/52) compared to the control group (43.1% 22/51) (difference, 8.8% [95% CI, −10.4% to 28.0%]; hazard
ratio [HR], 1.40 [95% CI, 0.79-2.49]; P = .26). There was no significant difference in 28-day mortality (15.7%
vs 24.0%; OR, 0.65 [95% CI, 0.29-1.46]; P = .30) or time from randomization to discharge (51.0% vs 36.0%
discharged by day 28; HR, 1.61 [95% CI, 0.88-2.93]; P = .12). Convalescent plasma treatment was associated
with a negative conversion rate of viral PCR at 72 hours in 87.2% of the convalescent plasma group vs
37.5% of the control group (OR, 11.39 [95% CI, 3.91-33.18]; P < .001).

•

Convalescent plasma treatment does not improve recovery for elderly patients
MedRxiv preprint: Systematic review found that younger patients treated with convalescent plasma
recovered in less than a week of receiving plasma treatment. Elderly patients, however, showed no
improvement in recovery time.

Interferon Lambda-1a
•

Interferon lambda-1a inhibits SARS-CoV-2 replication in novel mouse model of COVID-19
In a manuscript posted on bioRxiv, researchers from Stanford and University of North Carolina describe the
development of a new mouse model for COVID-19 where disease was more severe in aged mice. They also
demonstrate that clinical candidate interferon lambda-1a can potently inhibit SARS-CoV-2 replication in
primary human airway epithelial cells in vitro, and both prophylactic and therapeutic administration
diminished replication of virus in mice. A randomized clinical trial of the new therapy has started enrolling
120 patients at Stanford University.

Ivermectin
•

Modeling of repurposed drugs in S-protein inhibition
The study conducted virtual screening using docking calculations, a molecular modeling technique that
predicts how a protein interacts with small molecules. FDA approved drugs (n=9091) were screened. The
24 best-scored ligands had binding energy below –8.1 kcal/mol and were selected as potential candidates
to inhibit the SARS-CoV-2 S-protein by preventing the human cell infection and their replication. Ivermectin
was among those promising candidates that controlled replication in vitro.

Lenzilumab
•

Small study shows benefit of lenzilumab in high risk patients with severe pneumonia
MedRxiv preprint: Hospitalized patients with COVID-19 pneumonia and risk factors for poor outcomes were
treated with lenzilumab 600 mg intravenously for three doses through an emergency single-use IND
application. Clinical improvement was observed in 11 out of 12 (92%), with a significant improvement in
oxygenation and a median time to discharge of 5 days.

Liznhuagingwen
•

Randomized open trial on Lianhuaqingwen Capsules, a repurposed Chinese Herb
Lianhuaqingwen (LH) was studied in a prospective multicenter open-label randomized controlled trial
among confirmed COVID-19 cases. Patients (n = 284) were randomized to receive usual treatment alone or
in combination with LH capsules (4 capsules, thrice daily) for 14 days. Primary endpoints were resolution of

symptoms (fever, fatigue and coughing). The recovery rate was significantly higher in treatment group as
compared with control group (91.5% vs. 82.4%, P=0.022). The median time to symptom recovery was
shorter in treatment group (median: 7 vs. 10 days, P<0.001). Time to recovery of fever (2 vs. 3 days),
fatigue (3 vs. 6 days) and coughing (7 vs. 10 days) was also significantly shorter in treatment group (all
P<0.001). The rate of improvement in chest computed tomographic manifestations (83.8% vs. 64.1%,
P<0.001) and clinical cure (78.9% vs. 66.2%, P=0.017) was also higher in treatment group. Groups did not
differ in the rate of conversion to severe cases or viral assay findings (both P>0.05). No serious adverse
events were reported.

•

Efficacy and safety of Lianhuaqingwen (LH) Capsules, a repurposed Chinese herb
Phytomedicine: A prospective multicenter open-label randomized controlled trial on LH capsules was
performed on confirmed COVID-19 cases. Patients were randomized to receive usual treatment alone or in
combination with LH capsules (4 capsules, thrice daily) for 14 days. The primary endpoint was the rate of
symptom (fever, fatigue, coughing). The study included 284 patients (142 each in treatment and control
group) in the full-analysis set. The recovery rate was significantly higher in treatment group as compared
with control group (91.5% vs. 82.4%, p = 0.022). The median time to symptom recovery was markedly
shorter in treatment group (median: 7 vs. 10 days, p < 0.001). Time to recovery of fever (2 vs. 3 days),
fatigue (3 vs. 6 days) and coughing (7 vs. 10 days) was also significantly shorter in the treatment group (all p
< 0.001). The rate of improvement in chest computed tomographic manifestations (83.8% vs. 64.1%, p <
0.001) and clinical cure (78.9% vs. 66.2%, p = 0.017) was also higher in treatment group. However, both
groups did not differ in the rate of conversion to severe cases or viral assay findings (both p > 0.05). No
serious adverse events were reported.

Lopinavir/ritonavir
•

Evidence of effectiveness of lopinavir/ritonavir combined with pneumonia-associated
adjuvant drugs
One retrospective study (N=47 hospitalized patients with COVID-19) showed that compared with the
treatment of pneumonia-associated adjuvant drugs alone, the combination treatment with LPV/r and
adjuvant drugs has a more evident therapeutic effect in lowering the body temperature.

•

Antivirals do not reduce time of viral clearance, lopinavir/ritonavir delayed viral clearance
MedRxiv preprint: Guangzhou study examined 284 consecutive COVID-19 cases. 280 patients achieved viral
RNA clearance with a median length of 12 days (IQR: 8-16) after onset of illness. 66.1% of them had viral
RNA cleared within 14 days, and 89.3% within 21 days. Older age, severity of disease, time lag from illness
onset to hospital admission, fever, and corticosteroid use were associated with delayed clearance of viral
RNA. None of the antiviral regimens (chloroquine, oseltamivir, arbidol, and lopinavir/ritonavir) improved
viral RNA clearance. Lopinavir/ritonavir was associated with delayed clearance of viral RNA after adjusting
for confounders.

•

Neither lopinavir/ritonavir or arbidol provided virologic or clinical benefit in an RCT
In a randomized controlled trial (partially blinded) 34 patients with mild/moderate disease were assigned to
LPV/r, 35 to arbidol and 17 had no antiviral medication. There were no significant differences in duration of
viral shedding, rates of symptoms resolution or improvement of chest CT, or rates of progression to severe
states.

•

Early lopinavir-ritonavir failed trial had limitations - editorials suggest further study
NEJM: In this series of letters, authors discuss how late the interventions were performed and some
positive trends in the data that suggest the drug should not be abandoned yet.

•

Lopinavir-ritonavir (Kaletra) did not accelerate recovery or improve mortality rates
The study’s 199 patients with confirmed severe acute respiratory syndrome coronavirus 2 infection were
randomly assigned to receive standard care plus 400mg of lopinavir and 100mg of ritonavir twice a day for
14 days or standard care alone. For both groups the time to clinical improvement— the primary end
point—was a median of 16 days. Researchers stopped the intervention early for 13 patients who
experienced mainly gastrointestinal adverse events.

•

Lopinavir and Ritonavir may not reach effective concentrations: pharmacokinetic study
In this series of 8 patients admitted to a “normal care” ward because of COVID-19, the authors quantified
trough plasma concentrations of lopinavir and ritonavir by liquid chromatography–tandem mass
spectrometry. Trough concentrations are the lowest concentration reached by a drug before the next dose
is administered. Compared to patients with HIV, approximately 60- to 120-fold higher concentrations are
required to reach the assumed EC50 at trough levels, making effective treatment of COVID-19 with
lopinavir and ritonavir at the currently used doses unlikely.

•

Phase 2 RCT of IFN beta-1b, lopinavir–ritonavir, and ribavirin triple therapy yield
statistically significant decrease in viral shedding
This randomized controlled trial assessed patients from 6 Hong Kong hospitals. 86 were randomly assigned
to the combination group and 41 were assigned to the lopinavir-ritonavir control group. The combination
group received a 14-day regiment of lopinavir 400 mg and ritonavir 100 mg q12h, ribavirin 400 mg q12h,
and 3 doses of 8 million IU of interferon beta-1b on alternate days. The control group received 14 days of
lopinavir 400 mg and ritonavir 100 mg q12h. The combination group had a shorter median time (7 days)
from start of study treatment to negative nasopharyngeal swab compared to control group (12 days).
HR=4.37, (95% CI 1.86-10.24), p value = 0.0010. Researchers concluded that early triple antiviral therapy
was safe and superior to lopinavir–ritonavir alone in shortening the duration of viral shedding in patients
with mild to moderate COVID-19. The study did not have a placebo group, which makes it impossible to
assess the overall clinical benefit of the combination treatment.

•

Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets
Antiviral efficacies of lopinavir-ritonavir, HCQ sulfate, and emtricitabine-tenofovir for SARS-CoV-2 infection
were assessed in the ferret infection model. Taken together, all antiviral drugs tested marginally reduced
the overall clinical scores of infected ferrets but did not significantly affect in vivo virus titers. Despite the
potential discrepancy of drug efficacies between animals and humans, these preclinical ferret data should
be highly informative to future therapeutic treatment of COVID-19 patients.

LY-CoV555
•

Lilly begins world's first study of a potential COVID-19 antibody treatment in humans
Lilly press release: The first patients have been dosed in a Phase 1 study of LY-CoV555, the lead antibody
from Lilly's collaboration with AbCellera. The placebo-controlled study will investigate safety, tolerability,
pharmacokinetics, and pharmacodynamics in patients hospitalized with COVID-19 with results anticipated
by the end of June. If Phase 1 results show the antibody can be safely administered, Lilly will initiate a
Phase 2 proof of concept study to assess efficacy in vulnerable populations.

Melatonin
•

Melatonin as a potential adjuvant treatment for COVID-19
Authors postulate melatonin, through its indirect anti-viral actions, may play a role of adjuvant medication
in the regulation of immune system, inflammation and oxidation stress, and provide support for COVID-19

patients with ALI/ARDS and related complications. https://doi.org/10.1016/j.lfs.2020.117583 In support of
the original paper's proposal regarding melatonin use in COVID-19 cases, these authors discuss the direct
impact of melatonin on the pulmonary vasculature, citing animal studies in which melatonin had positive
vasodilatory effects in cases of pulmonary arterial hypertension in newborns. Based on the similarities of
COVID-19 with hypoxic pulmonary hypertension and edema, melatonin may be a possible addition to
therapy as it may promote pulmonary vascular protection.

Methylprednisolone
•

Methylprednisolone improves outcomes in hospitalized patients with CoVID-19
pneumonia
MedRxiv preprint: A small controlled trial (n = 85) of a short course of methylprednisolone showed
improvement of the composite endpoint of death, ICU admission or requirement of non-invasive
ventilation. MP was associated with a reduced risk of the composite endpoint in the intention-to-treat, agestratified analysis (combined risk ratio 0.55 [95% CI 0.33-0.91]; p=0.024). A decrease in C-reactive protein
levels was more pronounced in the MP group (p=0.0003). Hyperglycemia was more frequent in the MP
group.

Monalizumab
•

NKG2A receptor and COVID-19: new potential treatment target
A receptor on lymphocytes) is involved in host immune responses. On this basis, the authors hypothesize
that the anti-NKG2A monoclonal antibody monalizumab, currently under active clinical development for
the management of rheumatoid arthritis and several neoplastic disorders, could represent a viable way for
treatment of patients with severe COVID-19 infection, characterized by a sudden and marked reduction of
the antiviral activity of NK and CD8+cells

Niclosamide
•

Niclosamide anti-parasitic drug effective against coronavirus in animal tests
Reuters: South Korea’s Daewoong Pharmaceutical said its anti-parasitic drug niclosamide, used to treat
tapeworms, eliminated the novel coronavirus from ferrets' lung tissues and inhibited inflammation. The
company plans to start human clinical trials in July. Three other companies around the world are testing
niclosamide as a coronavirus treatment, but Daewoong is the only one that offers the drug in a form that is
not given orally, the company official told Reuters.

Nifedipine
•

Benefits of nifedipine and amlodipine in elderly patients hospitalized for COVID-19
A retrospective chart review study showed that patients treated with a calcium channel blocker (CCB) were
significantly more likely to survive than those not treated with a CCB (P<.01; p=0.0036). CCB patients were
also significantly less likely to undergo intubation and mechanical ventilation (P<.01; p=0.0026). Nifedipine
and amlodipine were found to be associated with significantly improved mortality and a decreased risk for
intubation and mechanical ventilation in elderly patients hospitalized with COVID-19.

Novaferon
•

Novaferon in randomized parallel group study outperforms lopinavir/ritonavir for viral
clearance
MedRxiv preprint: Novaferon, a novel protein drug approved for the treatment of chronic hepatitis B in
China, was shown to inhibit viral replication in infected cells and enable healthy cells to resist viral entry. In
a small randomized, open-label, parallel group study (n=89), both Novaferon alone and Novaferon with
Lopinavir/Ritonavir groups had significantly higher clearance rates on day 6 than the Lopinavir/Ritonavir
group (50.0% vs.24.1%, p = 0.0400, and 60.0% vs.24.1%, p = 0.0053).

NSAIDs
•

UK healthcare authorities advise against NSAIDs for fever in patients with suspected
COVID-19
Paracetamol should be used in preference to non-steroidal anti-inflammatory drugs for managing fever in
patients with suspected COVID-19 until more evidence is available on the safety of NSAIDs, the National
Institute for Health and Care Excellence advises in a rapid guideline on managing symptoms of covid-19 in
the community.

•

NSAIDs - No published evidence for or against their use in COVID-19 patients
Corticosteroids may be beneficial if utilized in the early acute phase of infection. Caution on use of NSAIDs
and corticosteroids in COVID-19 patients.

Optilimab
•

GSK to begin a trial with experimental drug to treat pneumonia related to COVID-19
GlaxoSmithKline found that otilimab, an experimental rheumatoid arthritis drug, could possibly ease the
devastating effect of the virus on the lungs but not suppress it directly. The randomized trial will enroll 800
people.

Oseltamivir
•

Antivirals do not reduce time of viral clearance, lopinavir/ritonavir delayed viral clearance
MedRxiv preprint: Guangzhou study examined 284 consecutive COVID-19 cases. 280 patients achieved viral
RNA clearance with a median length of 12 days (IQR: 8-16) after onset of illness. 66.1% of them had viral
RNA cleared within 14 days, and 89.3% within 21 days. Older age, severity of disease, time lag from illness
onset to hospital admission, fever, and corticosteroid use were associated with delayed clearance of viral
RNA. None of the antiviral regimens (chloroquine, oseltamivir, arbidol, and lopinavir/ritonavir) improved
viral RNA clearance. Lopinavir/ritonavir was associated with delayed clearance of viral RNA after adjusting
for confounders.

Peptide
•

In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2
The authors report the use of molecular dynamics simulation to design a peptide that can prevent the virus
membrane from fusing with the host cell. The authors plan to continue to simulate the peptide with
modification, and then test the blocking effect in cells and animal infections.

Phytochemicals
•

Natural product-derived phytochemical as potential agents against coronavirus virus
research
The authors conducted a review of 55 primary research articles on phytochemicals against different human
and animal coronaviruses identified from the PubMed database. Approximately 10 compounds have been
found to have potential for the inhibition of coronavirus in humans. Most of these compounds are
classified as polyphenols and/or contain a conjugated fused ring structure.

•

Phytochemicals' treatment potential structural chemistry
Researchers investigated the potential inhibitory effects of plant-extracted compounds (phytochemicals)
from fauna inhabited in Pakistan and India with previously known pharmacological activity and found 60
compounds with binding affinity to Mpro (main protease) of SARS-COV2. Among these compounds include
previously known anti-inflammatory compounds and antioxidants such as robustone, lycopene, and
isopomiferine.

Probiotics
•

Evidence summary for probiotics in treatment of COVID-19
A brief correspondence letter in the Lancet summarizes existing evidence for use of probiotics in COVID-19.
Probiotics are routinely used for COVID care in China, and RCTs have shown reduction in ventilator
associated pneumonia from probiotics versus placebo. Not all probiotics are the same.

Protease
•

HIV protease inhibitors and RNA-dependent RNA polymerase inhibitors showed
promising features
Along with these, Methisazone, an antiviral inhibitor of protein synthesis; CGP42112A, an angiotensin AT2
receptor peptide agonist; and Paritaprevir, an approved antiviral against Hepatitis C that blocks the NS3-4A
(HCV) serine protease are some of the novel treatment option against COVID-19 proposed.

•

Virtual screening and repurposing of FDA approved drugs against COVID-19 main
protease
Molecular modeling, virtual screening, docking, sequence comparison statistics and phylogenetics of the
COVID-19 main protease were investigated. The top 20 candidates comprised a broad-spectrum antiviral
(ribavirin), anti-hepatitis B virus (telbivudine), two vitamins (vitamin B12 and nicotinamide) and other
miscellaneous systemically acting drugs.

•

Targeting virus protease: drug candidates found through virtual screening of the ChEMBL
database
The main protease M(pro) of SARS-CoV-2 is a potential target for treatment of COVID-19. A M(pro)
homodimer structure suitable for docking simulations was prepared using a crystal structure. Structurebased virtual screenings of 1,485,144 compounds predicted 64 potential drugs (11 approved, 14 clinical,
and 39 preclinical drugs) to show high binding affinity with M(pro). Additional docking simulations for
predicted compounds with high binding affinity with M(pro) suggested that 28 bioactive compounds may
have potential as effective anti-SARS-CoV-2 drug candidates.

•

Plant-derived alkaloids and terpenoids as potential protease inhibitors
Using silico/computational approach, twenty African plant-derived alkaloids and terpenoids were identified
with high binding affinities to the SARS-CoV-2 and SARS-CoV 3-chymotrypsin-like protease.

•

In silico screening of natural phytochemical compounds against COVID-19
The authors created a phytochemical library of 318 phytochemicals from 11 plants which have been
reported as having antiviral, antibacterial or antifungal activity. It was subjected to virtual screening against
molecular targets; Main protease (Mpro) and Angiotensin-Converting Enzyme 2 (ACE2). The top 10
compounds were selected from each target.

•

Anti-nCoV drug chemical compounds from Indian spices identified to target SARS-CoV-2
main protease
The authors examined the structure of 45 chemical compounds from Indian spices using PubChem or Zinc
databases. Four small chemicals were further analyzed based on their binding affinity with SARS-CoV 2
main protease. The compounds Carnosol, Rosmanol, and Arjunglucoside-I demonstrated strong and stable
binding affinities to the protease’s active site.

•

Potential inhibitors for virus protease found by screening of 606 Million compounds
The authors computationally screened a library of over 606 million compounds for binding at the recently
solved crystal structure of the main protease (M(pro)) of SARS-CoV-2. After evaluation of potential offtarget binding, they report a list of 12 purchasable compounds, with binding affinity to the target protease
that is predicted to be more favorable than that of the cocrystallized peptidomimetic compound. In order
to quickly advise ongoing therapeutic intervention for patients, the authors evaluated approved antiviral
drugs and other protease inhibitors to provide a list of nine compounds for drug repurposing. Furthermore,
they identified the natural compounds (-)-taxifolin and rhamnetin as potential inhibitors of M(pro).
Rhamnetin is already commercially available in pharmacies.

RAAS
•

Renin-angiotensin-aldosterone (RAAS) inhibitors decrease mortality: review and metaanalysis
Preprint: Patients taking RAAS for hypertension, overall pooled estimates showed 35% less likely to die
from the virus compared to patients with hypertension not taking RAAS inhibitors (pooled RR= 0.65, 95%
Confidence Intervals (CI): 0.45-0.94).

•

RAAS inhibitors associated with better COVID-19 prognosis: a meta-analysis
Journal of Infection: 16 studies were included that involved 24,676 COVID-19 patients, and patients with
critical (n=4134) vs. non-critical (n=20,542) outcomes were compared. The use of ACEIs/ARBs is not
associated with higher risk of in-hospital-death and/or severe illness among hypertensive patients with
COVID-19 infection. On the contrary, effect estimate shows an overall protective effect of RAAS
inhibitors/blockers (ACEIs, ARBs, and/or ACEIs/ARBs) with approximately 23% reduced risk of death and/or
critical disease (OR: 0.768, 95%CI: 0.651-0.907, p=0.0018). The use of ACEIs (OR:0.652, 95%CI:0.478-0.891,
p=0.0072) but not ACEIs/ARBs (OR:0.867, 95%CI:0.638-1.179, p =NS) or ARBs alone (OR:0.810,
95%CI:0.629-1.044, p=NS) may explain the overall protection displayed by RAAS intervention combined.

Remdesivir
•

Clinical data support the use of Remdesivir for severe COVID-19
In 53 patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir,
clinical improvement was observed in 68%.

•

Intravenous remdesivir shows clinical benefit in the rhesus macaque model of SARS-CoV2 infection
Biorxiv preprint: Remdesivir in doses mimicking human dosing was started 12 hours after inoculation with
SARS-CoV-2 and continued through day six. Compared to vehicle solution-treated control animals, 1) virus
titers were significantly reduced as soon as 12 hours after initiation of treatment in bronchoalveolar
lavages (BAL) 2) blinded clinical scores were reduced, and 3) lung viral loads (but not nose and rectal swab
viral loads) were significantly lower and there was clear reduction in pneumonia (assessed by a veterinary
pathologist blinded to treatment) at necropsy 7 days after inoculation. Authors note that improved clinical
signs should not be confused with lack of infectiousness, and also that persistent nasal shedding could
mask significant antiviral effects in lung.

•

NIH, Gilead, Fauci announce successful remdesivir randomized placebo-controlled trial
n=1063
NIH Data safety and monitoring board (DSMB) recommended study termination based on clear clinical
benefit with significant shortening of median recovery time from 15 days to 11 days (p<0.001). There was a
trend toward reduced mortality in the treatment group (8% Tx vs 11.6% placebo, p=0.059). The
recommendation was based on data available to the DSMB last week, so additional endpoint data is likely
to be available when the manuscript is drafted. Gilead and NIH announce results early, with NIAID Director
Dr. Anthony Fauci discussing the results in a White House interview. DSMB saw clear clinical benefit and
notified study team so people on placebo could be offered drug. Dr. Fauci remarked that this reminded him
of the initial results with AZT treatment of AIDS, which were followed by improved efficacy as additional
drugs came on line. In light of demonstrated clinical efficacy of remdesivir, Dr. Fauci noted that future
randomized controlled trials (RCTs) will have to include remdesivir rather than placebo once remdesivir is
available. Gilead exploratory analysis supports earlier treatment: patients in the study who received
remdesivir within 10 days of symptom onset had improved outcomes compared with those treated after
10 days. Most common adverse events occurring in >10% of patients in either group were nausea (5-day:
10.0%, n=20/200 vs. 10-day: 8.6%, n=17/197) and acute respiratory failure (5-day: 6.0%, n=12/200 vs. 10day: 10.7%, n= 21/197). Grade 3 or higher liver enzyme (ALT) elevations occurred in 7.3% (n=28/385) of
patients, with 3.0% (n=12/397) of patients discontinuing remdesivir treatment due to elevated liver tests.
This report comes after a smaller (n=237) Chinese RCT published in Lancet (that did not meet its target
accrual due to reduction in local cases) showed similar trends in efficacy but failed to show significance.

•

Remdesivir trial in China shows poor outcomes – Gilead, manufacturer, disagrees
WHO was given early access to Chinese remdesivir RCT results (NCT04252664) for mild to moderate cases
and posted online. Before its removal, results showed 237 patients underwent randomization: 158
remdesivir and 79 control. No significant difference in time to clinical improvement (hazard ratio 1.23, 95%
CI 0.87-1.75), mortality at 28 days (13.9% vs 12.8%) or time to viral negativity. Treatment stopped early in
11.6% of treated vs. 5.1% of controls due to adverse events. A Gilead spokesperson said, "the post included
inappropriate characterization of the study." Gilead later said in a broader statement that the study ended
early due to low enrollment and, as a result, could not provide "statistically meaningful" conclusions. Even
as the results are inconclusive, "trends in the data suggest a potential benefit for remdesivir, particularly
among patients treated early in disease," Gilead said.

•

Structure of remdesivir
Researchers report in Science the structure of remdesivir, an antiviral that’s shown promise against the
SARS-CoV-2 virus, bound to both RNA and the viral polymerase – illuminating the mechanism the drug uses
to shut down viral reproduction.

•

US FDA issues an emergency use authorization for remdesivir for the treatment COVID19
Today, the U.S. Food and Drug Administration issued an emergency use authorization for the
investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19
in adults and children hospitalized with severe disease.

•

Remdesivir inhibits from SARS-CoV-2 RNA-dependent RNA polymerase: Mechanism of
action
The replication of SARS-CoV-2 requires the viral RNA-dependent RNA polymerase (RdRp), the target of the
antiviral drug, remdesivir, which acts as a non-obligate chain terminator.

•

No clinical difference between Remdesivir for 5 days or 10 days in an open-label trial
This is a randomized, open-label, phase 3 trial involving hospitalized patients with confirmed SARS-CoV-2
infection, oxygen saturation of 94% or less while they were breathing ambient air, and radiologic evidence
of pneumonia. Patients were randomly assigned in a 1:1 ratio to receive intravenous remdesivir for either 5
days or 10 days. All patients (N=397) received 200 mg of remdesivir on day 1 and 100 mg once daily on
subsequent days. The primary end point was clinical status on day 14, assessed on a 7-point ordinal scale.
After adjustment for baseline clinical status, patients in the 10-day group had a distribution in clinical status
at day 14 that was similar to that among patients in the 5-day group (P=0.14). The most common adverse
events were nausea (9% of patients), worsening respiratory failure (8%), elevated alanine aminotransferase
level (7%), and constipation (7%).

•

Highest number of clinical trials being conducted on hydroxychloroquine, followed by
remdemsivir
A systematic review of clinical drug trials showed that by the end of June we will have results of almost 20
trials involving 40000 patients for hydroxychloroquine and 5 trials with 4500 patients for remdesivir;
however, low statistical power is expected from the 9 clinical trials testing the efficacy of favipiravir or the 5
testing tocilizumab, since each one will recruit less than 1000 patients.

•

NIH announces trial combining antiviral remdesivir and antiinflammatory drug baricitinib
The NIAID-sponsored trial is expected to open at approximately 100 U.S. and international sites and enroll
more than 1000 participants. Baricitinib, taken orally, inhibits cytokine signaling in the body that plays a
role in causing inflammatory responses. The putative benefit of baricitinib for COVID-19 has been described
in a case series of critically ill patients who recovered. The combination of remdesivir and baricitinib has not
been evaluated in a large, randomized controlled treatment trial. One arrm will receive baricitinib tablets
orally and intravenous (IV) remdesivir, and the other will receive placebo tablets orally and IV remdesivir in
this double-blind study. The primary outcome is time to recovery, with secondary outcomes examining
severity and mortality.

•

Gilead partners with 5 generic drug-makers for remdesivir production
Gilead Sciences Inc announced Tuesday that it signed non-exclusive, royalty-free licensing pacts with five
generic drug companies (Jubilant Life Sciences Ltd, Cipla Ltd, Hetero Labs Ltd, Mylan NV, and Ferozsons
Laboratories Ltd) to make and sell remdesivir in 127 countries, including Afghanistan, India, North Korea,
Pakistan, and South Africa. The licensees will set their own prices for the generic product.

•

Double-blind RCT: remdesivir significantly decreased time to recovery
A double-blind, randomized, placebo-controlled trial was conducted on intravenous remdesivir in adults
hospitalized with Covid-19 with evidence of lower respiratory tract involvement (N=1063 patients
randomized). Preliminary results of the NIAID remdesivir RCT were published in NEJM after the Data and
Safety Monitoring Board recommended early unblinding of the results. The remdesivir group median

recovery time was 11 days (95% confidence interval [CI], 9 to 12), compared to 15 days (95% CI, 13 to 19)
for the placebo group (rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; P<0.001). The Kaplan-Meier
estimates of mortality by 14 days were 7.1% with remdesivir and 11.9% with placebo (hazard ratio for
death, 0.70; 95% CI, 0.47 to 1.04). Benefit was greatest in hospitalized patients requiring oxygen without
high flow oxygen, intubation or ECMO (ordinal scale 5) at enrollment with HR (95%CI) for median time to
recovery = 1.47 (1.17-1.84) and mortality by day 14 = 0.22 (0.08-0.58). Impact on recovery and mortality in
those who were sicker at entry (ordinal 6: high flow oxygen & ordinal 7: intubation or ECMO) was not
significant, but there were smaller numbers of study subjects in these groups. And, a higher proportion of
these subjects were still hospitalized at the time of the interim analysis. While it’s not possible to say that
sicker patients don’t benefit, it’s clear that those in the ordinal scale 5 group do benefit with significant
reduction in both time to recovery and mortality.

•

Five antivirals comparable to remdesivir in vitro
BioRxiv preprint: Swiss scientists discuss the identification of 5 antivirals which potently inhibited SARSCoV-2 replication and displayed equal or even higher antiviral efficacy to remdesivir. Compounds from the
antimicrobial "Pandemic Response Box" library were screened for inhibiting properties against SARS-CoV-2.
The five candidate compounds identified (chloroquine, NN-DNJ, PDNJ0803, URMC-099-C, and Retro-2.1)
have previously also been demonstrated to inhibit the replication of other 204 RNA-viruses such as
filoviruses, flaviviruses and picornaviruses. These five compounds should be further investigated for their
mode of action, safety and efficacy.

•

Remdesivir results mixed in moderate COVID-19 patients
Reuters: A late-stage safety and efficacy trial of remdesivir in 600 patients with moderate COVID-19 found
that 76% of patients treated for 5 days and 70% of patients treated for 10 days achieved clinical
improvement compared to only 66% of patients given standard care. While the 5-day treatment group did
achieve a significant increase in the percentage of patients who were improved, the percentage of patients
who were clinically improved in the 10-day treatment group did not achieve significance. These findings
indicate that remdesivir has some utility in treatment of moderate COVID-19 patients, but benefits are
likely modest and protocols need to be clarified.

•

Gilead's remdesivir shows promise in COVID-19 study on monkeys
Nature: Therapeutic remdesivir treatment initiated early during infection had a clinical benefit in SARS-CoV2-infected rhesus macaques. The data support early remdesivir treatment initiation in COVID-19 patients to
prevent progression to pneumonia. This article was reported on in our April 20, 2020 briefing when it was a
preprint.

Ruxolitinib
•

Ruxolitinib Phase II RCT shows encouraging results in treating COVID-19 cytokine storm
The Journal of allergy and clinical immunology: A Chinese prospective multicenter, single-blinded
randomized controlled phase II trial was performed on patients with severe COVID-19. 20 received
Ruxolitinib +standard of care (SoC) and 21 received SoC+ placebo. Treatment with Ruxolitinib +SoC was not
associated with significantly accelerated clinical improvement, although Ruxolitinib recipients had a
numerically faster clinical improvement (12 [IQR 10 -19] days versus 15 [IQR 10-18] days, log-rank test P =
0.147). 18 (90%) patients from the Ruxolitinib group showed CT improvement at day 14 compared with 13
(61.9%) patients from the control group (P = 0.0495). Three patients in the control group died of
respiratory failure, with 14.3% overall mortality at day 28. No patients died in the Ruxolitinib group, but
mortality protection failed to reach significance (p=0.089). Ruxolitinib was well tolerated with low toxicities
and no new safety signals. Levels of 7 cytokines were significantly decreased in the Ruxolitinib group in
comparison to controls. Patients in the Ruxolitinib group had a significantly shorter median time of

recovery from lymphopenia (5 [IQR 2-7] days versus 8 [IQR 2-11] days, log-rank test P = 0.033). Small study
size was a limitation but are informative for further large-scale trials.

Stem Cell Therapy
•

Stem cell therapy: Consideration as a potential treatment for SARS-COV-2-induced lung
injury
Acute lung injury (ALI), results from a wide variety of lung injuries. Viral infection is the main cause of
morbidity and mortality in ALI and acute respiratory distress syndrome (ARDS) patients. Future research on
stem cell-based therapy for lung injury caused by influenza viruses including SARS-CoV-2 is therefore
required.

Tetracyclines
•

Therapeutic Potential for Tetracyclines in the Treatment of COVID-19
Highly lipophilic antibiotics. Chelate zinc compounds on matrix metalloproteinases (MMPs). Coronaviruses
rely on host MMPs for survival, cell infiltration, cell to cell adhesion, and replication. Tetracyclines overall
are much safer agents than other potential agents that have been considered to treat COVID-19, such as
chloroquine or antiretroviral drugs.

Tocilizumab
•

Tocilizumab had no effect on 7-day mortality or ICU admission in retrospective study
This a retrospective cohort analysis of 112 Italian patients of whom 42 were included in a propensity score
match. matched based on propensity scores. After multivariate logistic regression there was no observed
statistically significant effect on 7-day mortality or ICU admission.

•

Tocilizumab decreases mortality rate and improves clinical course in patients in
respiratory failure
An article published in the European Journal of Internal Medicine by Italian researchers reports the results
of a retrospective cohort study of 85 patients in respiratory failure not requiring mechanical ventilation. 23
of the patients received standard of care (SOC) and 62 of them received SOC + tocilizumab. The results
show decreased mortality and improved clinical course in patients receiving tocilizumab. Daily hazard
ration of death was 0.035 (95% CI, 0.004 to 0.347; p = 0.004). The overall mortality rate of patients
receiving tocilizumab v SOC was 8% v. 58%. 64.8% of the patients receiving tocilizumab had an improved
clinical course and 27% worsened, whereas 100% of controls worsened and needed mechanical ventilation.

•

Use of subcutaneous tocilizumab in patients with Covid-19 pneumonia
In a letter to the editor in Journal of Medical Virology, Italian authors discuss three cases of patients with
Covid-19 pneumonia not requiring mechanical ventilation who were treated with a single dose of
Tocilizumab administrated, for the first time, subcutaneously. The authors observed favorable clinical
outcomes (e.g. decreased fever, weaning of oxygen therapy) and improvements in inflammatory
biomarkers, such as IL-6.

•

Tocilizumab for severe COVID-19 pneumonia: uncontrolled series study
A prospective series of 100 inpatients with COVID-19 pneumonia and ARDS requiring ventilatory support
was analyzed to determine whether intravenous administration of tocilizumab (TCZ), a monoclonal
antibody that targets the interleukin 6 receptor, was associated with improved outcome. Out of 100
treated patients 43 received TCZ in the ICU, while 57 in the general ward as no ICU beds were available.
Overall, at 10 days the respiratory condition was improved or stabilized in 77 (77%) of patients, of whom 61

showed a significant clearing of diffuse bilateral opacities on chest x-ray and 15 were discharged from the
hospital. Respiratory condition worsened in 23 (23%) patients, of whom 20 (20%) died. During the 10-day
follow-up, three cases of severe adverse events were recorded: two patients developed septic shock and
died, one had gastrointestinal perforation requiring urgent surgery and was alive at day 10. The response
to TCZ was rapid, sustained, and associated with significant clinical improvement. The data stem from an
uncontrolled series and a causal inference cannot be established.

•

Tocilizumab in severe COVID-19: preliminary weak evidence of effectiveness
Preliminary data from a small (N=21) single arm retrospective study show that tocilizumab (Il-6 receptor
blocker) adjunctive to the standard care improved clinical outcomes (symptoms, hypoxemia, and CT
opacity) immediately in severe and critical COVID-19 patients. The authors conclude that Tocilizumab is an
effective treatment to reduce mortality in COVID-19, however, since no control arm was used, evaluation
of the efficacy is challenging.

•

Tocilizumab as supportive treatment: systemic review
This is a systemic review of 63 articles on tocilizumab (TCZ) for supportive treatment. TCZ is not FDA
approved for COVID-19 use but is approved for cytokine release syndrome (CRS). Contraindicated in active
or latent TB, CBC abnormalities, and hepatitis. Ongoing RCTs may determine whether TCZ is effective in
COVID-19.

•

Multicenter study of Tocilizumab in patients with severe COVID-19
A cohort of 63 hospitalized adults with severe Covid-19 received a trial of Tocilizumab in a prospective,
open, single arm study. No evaluation of efficacy was possible in this single-arm study.

•

Intravenous tocilizumab has no clinical impact on SARS-CoV-2 pneumonia patients
Tocilizumab, a humanized monoclonal antibody, targets IL-6 receptors blocking downstream proinflammatory effects of IL-6. In a prospective study of 51 Italian patients hospitalized with severe COVID-19
pneumonia, tocilizumab intravenous treatment revealed a significant drop in body temperature and CRP
value and increase in lymphocyte counts. Tocilizumab treatment therefore seem to have beneficial effect
on fever and inflammatory markers without any impact on clinical outcome.

•

Tocilizumab therapy reduced ICU admissions and/or mortality in COVID-19 patients
A retrospective case-control study (n=45) in France compared the outcomes of COVID-19 treated with
tocilizumab (TCZ) (n=20) and patients without TCZ (n=25). Patients treated with TCZ had a lower death
and/or ICU admissions rate than patients treated without it (25% vs 72%, p=0.002), despite having a higher
Charlson co-morbidity index, higher levels of oxygen therapy, and poorer biological findings.

Vaccines
•

Modified smallpox based SARS-CoV-2 vaccine induces strong neutralizing antibody
response
bioRxiv preprint: A vaccine candidate using the smallpox vaccine virus (vaccinia ankara) shows good
immune response in mice when the full spike protein is included. The results comparing two versions of
MVA vaccines expressing either the full length prefusion stabilized spike or secreted S1 demonstrated that
while both immunogens induce strong binding antibody response to spike only the former induces a strong
neutralizing antibody response against the SARS-CoV-2.

•

New vaccine provides protection against SARS-CoV-2 challenge: an animal study
BioRxiv preprint: Israel researchers generated a recombinant Vesicular Stomatitis Virus (VSV)-∆G-spike
vaccine, in which the glycoprotein of VSV was replaced by the spike protein of the SARS-CoV-2. The
vaccination of hamsters with recombinant VSV-∆G-spike resulted in rapid and potent induction of

neutralizing antibodies against SARS-CoV-2. Importantly, single-dose vaccination was able to protect
hamsters against SARS-CoV-2 challenge, as demonstrated by the abrogation of body weight loss of the
immunized hamsters compared to unvaccinated hamsters. Whereas lungs of infected hamsters displayed
extensive tissue damage and high viral titers, immunized hamsters’ lungs showed only minor lung
pathology, and no viral load. Taken together, the authors suggest recombinant VSV-∆G-spike as a safe,
efficacious and protective vaccine against SARS-CoV-2 infection.

•

Engineered human mesenchymal stem cells can serve as a novel vaccine platform
BioRxiv preprint: The authors describe the engineered human mesenchymal stem cells (hu-MSC)
expressing SARS-CoV-2 proteins which serve as a small device which can be gradually cleared by the
immune system. After 20 days of immunization almost all the mice had antibody production in serum (7/8),
and at least 50% of the mice showed strong positive antibody expression. The antibody response tests
showed that this approach is effective and fast for use as a novel vaccine platform.

•

Immunogenicity of vaccination with the replication-deficient viral vectored vaccine
candidate
BioRxiv preprint: Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replicationdeficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein was initiated in
April 2020 following non-human primate studies using a single immunization. The authors compared the
immunogenicity of one or two doses of ChAdOx1 nCoV-19 in both mice and pigs. Whilst a single dose
induced antigen-specific antibody and T cells responses, a booster immunization enhanced antibody
responses, particularly in pigs, with a significant increase inSARS-CoV-2 neutralizing titers.

•

A review on COVID-19 vaccine development
A review of COVID-19 vaccine candidates and vaccine development platforms is provided.

•

Virus spike protein a potential vaccine candidate
The spike (S) protein mediates entry of SARS-CoV-2 into cells expressing the angiotensin-converting
enzyme 2 (ACE2). It engages ACE2 through its receptor-binding domain (RBD). These rodent data suggest
that an RBD-based vaccine for SARS-CoV-2 could be safe and effective.

•

Moderna receives $483 million BARDA award for COVID-19 vaccine development
Moderna said BARDA funding would support the vaccine’s clinical development program, as well as the
scale-up manufacture of the vaccine candidate, mRNA-1273, in 2020. The experimental vaccine is being
tested in an early-stage trial conducted by the U.S. National Institutes of Health, and Moderna expects to
begin mid-stage trial in the second quarter.

•

More than 90 vaccines are being developed for SARS-CoV-2
Nature News: This guide outlines the 90+ vaccines currently in development, including virus, viral-vector,
nucleic-acid, protein-based, and virus-like particle vaccines. At least six research groups have begun safety
trials with volunteers.

•

An experimental vaccine protects from infection with SARS-CoV-2 in rhesus macaque
model
A team at the Peking Union Medical College in Beijing injected rhesus macaques with three doses of an
inactivated SARS-CoV-2 vaccine. Four animals given a high vaccine dose had no detectable virus in their
throat or lungs seven days after infection. Animals that received a lower dose showed some signs of
infection, but levels of virus were much lower than in animals that received no vaccine. The company has
received approval to start human safety trials.

•

COVID-19 vaccine will require funded infrastructure and global cooperation
The ability to manufacture hundreds of millions to billions of doses of vaccine requires the vaccinemanufacturing capacity of the entire world. Although new technologies and factories can be developed to
sustain production, there is an immediate need to fund the necessary biomanufacturing infrastructure.
Cost, distribution system, cold chain requirements, and delivery of widespread coverage are all potential
constriction points in the eventual delivery of vaccines to individuals and communities. All of these issues
require global cooperation among organizations involved in health care delivery and economics.

•

French pharmaceutical giant rescinds previous statement and promises equal distribution
of vaccine
The CEO of Sanofi pharmaceuticals, Paul Hudson, has angered French officials after he told Bloomberg the
U.S. could get priority access to any vaccines produced there. The French Prime Minister responded by
saying equal distribution of the vaccine to all countries is "non-negotiable." Hudson has since apologized
and promised for equal distribution. Sanofi has two vaccine projects, one partnering with Britain and the
other with the U.S. company Translate Bio.

•

Childhood BCG vaccination does not protect against COVID-19 in adulthood
In a retrospective observational study published in JAMA, researchers from Tel Aviv University, Israel,
compared the COVID-19 positivity rate in 3064 likely BCG vaccinated people born between 1979 and 1981,
and 2869 likely unvaccinated people born between 1983 and 1985. No significant difference in positivity
rate was observed between the two groups, suggesting that BCG vaccination in childhood might not have a
protective effect against COVID-19 in adulthood as suggested in another opinion paper.

•

Rapid development of an inactivated vaccine candidate for SARS-CoV-2
Chinese researchers report in Science the pilot-scale production of a purified inactivated SARS-CoV-2 virus
vaccine candidate (PiCoVacc), which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and
non-human primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a
possible broader neutralizing ability against SARS-CoV-2 strains. Three immunizations using two different
doses (3 μg or 6 μg per dose) provided partial or complete protection in macaques against SARS-CoV-2
challenge without observable antibody-dependent enhancement of infection. This data strongly supports
clinical development of SARS-CoV-2 vaccines for humans.

•

WHO plans to compare multiple vaccines in one trial
The WHO sketched out plans for a clinical trial that will test numerous vaccines in a single study. Some
developers and funders have plans for their own efficacy trials. But key questions remain, such as which
vaccines will be tested first — or at all — and how their effectiveness will be measured and compared.

•

SARS-CoV-2 S structure may further inform vaccine design
Using a site-specific mass spectrometric approach, the authors mapped the glycan-processing states across
the trimeric viral spike. They show how SARS-CoV-2 S glycans differ from typical host glycan processing,
which may have implications in viral pathobiology and vaccine design.

•

European vaccine expanding to US – possible 20 million doses by the end of 2020
BioNTech initiated a clinical trial for a vaccine in Europe last month, with Pfizer now bringing the trial to the
United States. It will begin with four vaccine candidates being tested on 360 healthy individuals, split into
two groups based on age (young and old). The vaccine uses synthetic mRNA technology, allowing for faster
development. The companies plan to expand the trial to 8,000 individuals in the U.S. given the first phase
proves safe and claim they will have the capacity to administer up to 20 million doses by the end of 2020 if
FDA approved.

•

Oxford and AstraZeneca COVID-19 vaccine candidate to move to larger human trials
Oxford University and AstraZeneca are recruiting around 10,000 adults and children in Britain for trials of
an experimental coronavirus vaccine, a day after receiving U.S. backing worth up to $1.2 billion.
Researchers are mainly looking for healthcare staff and other public-facing workers to join the trial as in
order to get a clear signal on the vaccine’s efficacy.

•

DNA vaccine protective against SARS-CoV-2 in rhesus macaques
Study developed a series of DNA vaccine candidates expressing different forms of the SARS-CoV-2 Spike (S)
protein and evaluated them in 35 rhesus macaques. Vaccinated animals developed humoral and cellular
immune responses, including neutralizing antibody titers comparable to those found in convalescent
humans and macaques infected with SARS-CoV-2. Following vaccination, all animals were challenged with
SARS-CoV-2, and the vaccine encoding the full-length S protein resulted in >3.1 and >3.7 log10 reductions
in median viral loads in bronchoalveolar lavage and nasal mucosa, respectively, as compared with sham
controls. Vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an
immune correlate of protection. These data demonstrate vaccine protection against SARS-CoV-2 in
nonhuman primates.

•

Operation Warp Speed selects billionaire scientist’s COVID-19 vaccine for monkey tests
Science
Science: Billionaire Soon-Shiong says after he and his team made a Zoom presentation to HHS on 9 April,
they were invited to submit a full proposal and told that their vaccine would be among the candidates that
Warp Speed assesses in head-to-head monkey studies. Soon-Shiong’s companies, the publicly traded Nant
Kwest and the privately held Immunity Bio, have not published any data on their vaccine, which takes an
unusual approach to stimulating an immune response against SARS-CoV-2. Operation Warp Speed has
plans to whittle down 14 candidates from its initial selection to about eight for early stage human trials.

•

Vaccines inducing antibodies targeting SARS-CoV-2 receptor binding domain may be
broadly effective
MedRx preprint: Virus entry into cells depends on the receptor binding domain (RBD) of the SARS-CoV-2
spike (S) protein. ELISA assays performed on the plasma of 149 convalescent patients revealed low titers of
rare, but recurring RBD-specific antibodies in every individual tested. Despite low titers, antibodies to 3
distinct epitopes on RBD neutralized at half-maximal inhibitory concentrations (IC50s) as low as single digit
ng/mL. Females were found to have lower anti-RBD, anti-S IgG titers and overall lower neutralizing activity
than males.

•

A plan to test over six vaccines in 100,000 volunteers is taking shape
Plans to test multiple vaccine candidates simultaneously in July are underway in the US. Vaccine
manufacturers are agreeing to share trial networks if a given vaccine fails. Vaccines from Moderna and
Astrazeneca and others from the Operation Warp Speed shortlist will be tested. Fourteen other vaccines
may be tested as part of the effort if they are able to finish preliminary testing by late June.

•

Moderna's experimental coronavirus vaccine gets FDA's 'fast track' status
Moderna Inc is working on an mRNA vaccine that has been approved for "fast track" status making it
eligible for "priority review", under which the FDA aims to decide on approving the drug within six months.
A late phase trial is expected to start sometime in the early summer. The project had previously received
$483 million in funding from the U.S. government to accelerate development and is one of over 100
projects seeking to develop a vaccine globally.

•

First human vaccine tests by Novavax underway
Novavax indicated Phase 1 trial in Australia would involve about 130 healthy participants aged 18 to 59,
with a second phase to be conducted later in several countries. The Phase 2 trial will assess immunity,

safety and COVID-19 disease reduction in a broader age range. Novavax launches its first coronavirus
vaccine test on humans.

•

CanSino Biologics coronavirus vaccine appears safe in first human trial
A phase I trial of adenovirus vaccine developed in Wuhan was found to be safe at low, medium, and high
doses. The trial demonstrated that a single dose of the new adenovirus type 5 vectored COVID-19 (Ad5nCoV) vaccine produces virus-specific antibodies and T cells in 14 days. A Phase II trial is currently
underway, also in Wuhan.

•

Useful output from respiratory syncytial virus vaccine engineering
A stabilized form of the respiratory syncytial virus (RSV) fusion (F) protein has been explored as a vaccine to
prevent viral infection because it presents several potent neutralizing epitopes. This method could be used
to optimize interventions for COVID19.

•

More than 90 vaccines are being developed against SARS-CoV-2 across the world
Nature: More than 90 vaccines are being developed against SARS-CoV-2 across the world. At least six
groups have begun injecting formulations into volunteers in safety trials. A graphical guide is presented
explaining each vaccine design.

•

Efforts in COVID-19 vaccine development in Africa
Apart from South Africa, Kenya is the second African country awaiting approval for the COVID-19 vaccine
trial.

•

Coronavirus vaccine trials delivered their first results but promise unclear
Nature: More than 90 vaccines are being developed against SARS-CoV-2 by research teams in companies
and universities across the world. Researchers are trialing different technologies, some of which haven’t
been used in a licensed vaccine before. At least six groups have already begun injecting formulations into
volunteers in safety trials; others have started testing in animals. Nature’s graphical guide explains each
vaccine design (https://www.nature.com/articles/d41586-020-01221-y). Moderna revealed its COVID-19
vaccine triggered an immune response in people, and protected mice from lung infections with the
coronavirus SARS-CoV-2. Tests of other fast-tracked vaccines show that they have prevented infections in
the lungs of monkeys exposed to SARS-CoV-2, but not in some other parts of the body. A vaccine being
developed at the University of Oxford, UK, that is also in human trials — protected six monkeys from
pneumonia, but the animals’ noses harbored as much virus as did those of unvaccinated monkeys,
researchers reported1 last week in a bioRxiv preprint. A Chinese group reported similar caveats about its
own vaccine’s early animal tests this month. Despite uncertainties, all three teams are pressing ahead with
clinical trials

•

Moderna phase 3 trial will begin in July
Forbes: The phase 3 trial of Moderna’s experimental vaccine for COVID-19 will begin in July with 30,000
patients. A phase 3 trial follows testing for safety and is designed as a randomized controlled trial to
establish benefit of the vaccine over placebo. The trial will include primarily US sites but also international
sites and is the final step before potential approval by the FDA for general use.

•

Advances in skin science may enable development of COVID-19 vaccine
Journal of the American Academy of Dermatology: A commentary and review showed the potential of
cutaneous delivery strategies for vaccines and immune-modulation therapies via biotechnology such as
microneedle arrays. These approaches may allow for the development of novel vaccine strategies and
immunotherapies, as well as negative immunization strategies for immune regulation in the treatment of
systemic allergy and autoimmune diseases.

Velpatasvir, velpatasvir/sofosbuvir, ledipasvic/sofosbuvir
•

Virtual screening reveals velpatasvir, ledipasvir, and other potential drug repurposing
candidates
16 purchasable drug candidates were screened and proposed with a 3D SARS-CoV-2 3C-like protease
molecular model. The antivirals ledipasvir or velpatasvir are particularly attractive as therapeutics with
minimal side effects. The drugs Epclusa (velpatasvir/sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) could
be effective owing to their dual inhibitory actions on two viral enzymes.

OTHER
•

Host transcriptome-guided drug repurposing for COVID-19 treatment: a meta-analysis
based approach
PeerJ: In a computational study, the authors adopted a host transcriptome-based drug repurposing
strategy utilizing the publicly available high throughput gene expression data on SARS-CoV-2 and other
respiratory infection viruses. Based on the consistency in expression status of host factors in different cell
types and previous evidence reported in the literature, pro-viral factors of SARS-CoV-2 identified and
subject to drug repurposing analysis based on DrugBank and Connectivity Map (CMap) using the web tool,
CLUE. The upregulated pro-viral factors such as TYMP, PTGS2, C1S, CFB, IFI44, XAF1, CXCL2, and CXCL3
were identified in early infection models of SARS-CoV-2. By further analysis of the drug-perturbed
expression profiles in the connectivity map, 27 drugs that can reverse the expression of pro-viral factors
were identified, and importantly, twelve of them reported to have anti-viral activity. The direct inhibition of
the PTGS2 gene product can be considered as another therapeutic strategy for SARS-CoV-2 infection and
could suggest six approved PTGS2 inhibitor drugs for the treatment of COVID-19. The computational study
could propose candidate repurposable drugs against COVID-19, and further experimental studies are
required for validation.

•

Pixatimod (PG545) show promise as a potent virus inhibitor
bioRxiv preprint: Pixatimod (PG545), a clinical-stage heparan sulfate mimetic, has demonstrated in
laboratory testing to be a potent inhibitor of glycosidase heparanase, and has known anti-cancer, antiinflammatory and also antiviral properties. Pixatimod inhibits binding of recombinant S1 RBD to Vero cells
which express the ACE2 receptor. It effectively inhibits viral infection of Vero cells. Importantly, its potency
is well within its safe therapeutic dose range.

•

Antithrombotic therapies in COVID-19 disease: a systematic review
Journal of General Internal Medicine: Incidence of thromboembolism among hospitalized patients with
COVID-19 ranged from 25 to 53% in 4 retrospective series. Authors state review was limited by poor quality
of source studies including unclear patient selection protocols, lack of reporting or adjustment for patient
baseline characteristics, inadequate duration of follow-up, and partial reporting of outcomes.

•

Repurposing old drugs as antiviral agents for coronaviruses: 15 candidates identified
MedRxiv preprint: The authors screened approximately 250 existing drugs or pharmacologically active
compounds for their inhibitory activities against feline infectious peritonitis coronavirus (FIPV) and human
coronavirus OC43 (HCoV-OC43), a human coronavirus in the same genus (Betacoronavirus) as SARS-CoV-2.
15 out of the 252 drugs or pharmacologically active compounds screened were found to be active against
both FIPV and HCoV-OC43, with EC50 values ranging from 11 nM to 75 muM. They are all old drugs as
follows, anisomycin, antimycin A, atovaquone, chloroquine, conivaptan, emetine, gemcitabine,
homoharringtonine, niclosamide, nitazoxanide, oligomycin, salinomycin, tilorone, valinomyci, and
vismodegib.

•

The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID19 infection
Inflammation Research: Novel Coronavirus disease 2019 (COVID-19), is an acute respiratory distress
syndrome (ARDS). It has proven that COVID-19 infection in some elderly critical adults leads to a cytokine
storm, characterized by severe systemic elevation of several pro-inflammatory cytokines. A cytokine storm
can induce edematous, ARDS, pneumonia, as well as multiple organ failure in aged patients. It is far from
clear till now why cytokine storm induces in only COVID-19 elderly patients, and not in young patients.
However, it seems that aging is associated with mild elevated levels of local and systemic pro-inflammatory
cytokines, which is characterized by "inflamm-aging". It is highly likely that "inflamm-aging" is correlated to
increased risk of a cytokine storm in some critical elderly patients with COVID-19 infection. This review was
to summarize experimental data and clinical observations that linked the pathophysiology mechanisms of
"inflamm-aging", mild-grade inflammation, and cytokine storm in some elderly adults with severe COVID-19
infection.

•

Stilbene-based natural compounds as promising drug candidates against COVID-19
The current study aimed to repurpose stilbenoid analogs against SARS-CoV-2 spike protein and human
ACE2 receptor complex for their affinity and stability using molecular dynamics simulation and binding free
energy analysis based on molecular docking. 4 compounds were probed for binding affinity using molecular
docking showing good affinity. Stilbene based compounds in general and resveratrol can be promising antiCOVID-19 drug candidates acting through disruption of the spike protein.

•

Hypercoagulation and antithrombotic treatment in COVID-19: systematic review
A systematic review reports clinical studies on laboratory parameters: d-dimer, platelet counts,
prothrombin time, activated partial thromboplastin time, alanine aminotransferase, and aspartate
aminotransferase. Trials assessing efficacy of antithrombotic treatment, including aspirin or low-molecularweight heparin (LMWH), should be planned.

•

One dose of ChAdOx1 MERS provides protective immunity in animal study
Exploring MERS-CoV, researchers showed that rhesus macaques seroconverted rapidly after single
intramuscular vaccination with ChAdOx1 MERS. The vaccine protected against respiratory injury and
pneumonia and reduced viral load in lung tissue. MERS-CoV replication in type I and II pneumocytes of
ChAdOx1 MERS vaccinated animals was absent. A prime-boost regimen of ChAdOx1 MERS boosted
antibody titers, and viral replication was completely absent from the respiratory tract tissue of these rhesus
macaques. This is the first time that broad protection after a single vaccination has been shown for any
MERS-CoV vaccine. The data support further clinical development of ChAdOx1 MERS.

•

Bee venom and potential tolerance to SARS-CoV-2
Survey of beekeepers (n = 5115) in Wuhan found none of them had COVID-19 symptoms. They then
surveyed apitherapy patients (n = 121), including those exposed to known COVID-19 cases without
protective measures, and found none of them had symptoms. Authors suggest all subjects have been stung
by bees and could be the key in their apparent immunity. The authors suggest animal trials to determine
the significance of this relationship.

•

Cytokine storm interventions may reduce disease progression to ARDS and death
Retrospective study (n = 41) discusses potential intervention against cytokine storm causing pneumonia
and multi-organ failure. They considered treatment with neutralizing antibodies, IFN, inhibition of oxidized
phospholipids, sphingosine-1-P receptor 1 agonist, inhibition of monocyte activation, and continuous renal
replacement therapy. Authors believe controlling inflammatory factors can help decrease progression to
ARDS and mortality.

•

Liu Shen capsule, a traditional Chinese medicine, found to decrease virus replication in
lab setting
Liu Shen (LS) showed a dose-dependent effect of LS on infected cells (Vero E6) leading to reduced viral
particle formation and viral-induced cell death. Quantification of mRNA levels on a different set of LStreated infected cells (Huh-7) using rt-pcr showed a decrease in production of pro-inflammatory cytokines
and components of the NF-κB signaling pathway.

•

Respiratory rehabilitation in elderly with COVID-19: A randomized controlled study
This was a prospective, randomized open-label controlled study, recruiting 72 elderly participants, of which
36 were randomly underwent respiratory rehabilitation, with the others getting no treatment. Six-week
respiratory rehabilitation improved respiratory function, quality of life and anxiety of elderly patients with
COVID-19, but it had little improvement in depression.

•

Targeting the inflammatory cascade with IL-1 blockade in moderate to severe COVID-19
pneumonia
Case series of 9 adult patients with moderate-to-severe COVID-19 pneumonia who were treated with antiIL-1 blocking by anakinra in an attempt to prevent exaggerated host immune response. This proof-ofconcept study showed promising results and should help encourage larger controlled studies to investigate
effectiveness of IL-1 blockade in the treatment of COVID-19.

•

Clinical benefits of Chinese traditional medicines against COVID-19
The present review summarizes the basic information, clinical evidence and published literatures of
recommended CTMs against COVID-19.

•

Cytokine storm in COVID-19: pathogenesis and overview of treatment
Clinical Rheumatology review article: Impairment of SARS-CoV-2 clearance due to genetic and viral
features, lower levels of interferons, increased neutrophil extracellular traps and increased pyroptosis
create a background for severe disease course complicated by macrophage activation syndrome and
cytokine storm. Various genetic mutations may also constitute a risk factor for severe disease course and
occurrence of cytokine storm in COVID-19. Once immunologic complications occur, anti-viral treatment
alone is not enough and should be combined with appropriate anti-inflammatory treatment. Antirheumatic drugs, which are tried for managing immunologic complications of COVID-19 infection, are
discussed including chloroquine, HCQ, JAK inhibitors, IL-6 inhibitors, IL-1 inhibitors, anti-TNF-alpha agents,
corticosteroids, intravenous immunoglobulin, and colchicine.

•

Benefits of adjunctive herbal medicine for COVID-19: a meta-analysis
In 7 randomized clinical trials with a total of 855 patients a combined therapy of herbal medicine +Western
medicine was compared with Western medicine alone. The combined therapy significantly improved the
total effective rate (RR=1.23, 95% CI 1.13 to 1.34, p < 0.001), cough symptom disappearance rate (RR=1.45,
95% CI 1.12 to 1.89, p = 0.005), and sputum production symptom disappearance rate (RR=1.73, 95% CI
1.19 to 2.50, p = 0.004). Beneficial effects of the combined therapy were also seen in traditional Chinese
medicine syndrome score of cough (MD -1.18, 95% CI -1.34 to -1.03, p < 0.001), fever (MD -0.62, 95% CI 0.79 to -0.45, p < 0.001), dry and sore throat (MD -0.83, 95% CI -1.45 to -0.20, p = 0.009), and fatigue (MD 0.60, 95% CI -1.04 to -0.17, p = 0.007). The overall risk of bias of the included studies was unclear. No
serious adverse events were reported.

•

SARS-CoV-2 infection induces protective immunity in rhesus macaques
Authors developed a rhesus macaque model of SARS-CoV-2 infection and observed that macaques (n = 9)
had high viral loads in the upper and lower respiratory tract, humoral and cellular immune responses, and
pathologic evidence of viral pneumonia. Following initial viral clearance, animals were rechallenged with
SARS-CoV-2 and showed 5 log10 reductions in median viral loads in bronchoalveolar lavage and nasal

mucosa compared with primary infection. Anamnestic immune responses following rechallenge suggested
that protection was mediated by immunologic control.

•

Protein simulation identifies drugs targeting critical SARS-CoV-2 enzymes
A study modeling protein interactions identified existing and potential new drugs targeting critical viral
enzymes. Talampicillin, Lurasidone, and two novel drug-like compounds bind protease Mpro. Rubitecan,
Lopazolam, and two novel drug-like compounds bind TMPRSS2, a serine membrane protein used for cell
entry. Analysis used Protein Data Bank archive with existing proteins showing >90% homology with viral
proteins.

•

Depriving iron supply to the virus represents a promising adjuvant therapeutic against
viral survival
Iron-containing enzymes are most likely required for coronavirus replication. Limiting iron via chelators (i.e.
deferiprone, and deferoxamine) or increasing ferroportin expression has been shown to prolong survival of
patients with AIDS. Not much is known about iron regulation in COVID patients, but from other viral
infections, we can deduce that iron chelation may be a beneficial in treating COVID.

•

Prioritization of potential anti-SARS-CoV-2 drug repurposing based on pharmacokinetics
In vitro anti-SARS-CoV-2 activity data was digitized from all available publications. EC90 values were then
expressed as a ratio to the achievable maximum plasma concentrations (Cmax) reported for each drug
after administration of the approved dose to humans (Cmax/EC90 ratio). Hydroxychloroquine, chloroquine,
mefloquine, atazanavir (boosted with ritonavir), tipranavir (boosted with ritonavir), ivermectin,
azithromycin and lopinavir (boosted with ritonavir) were all predicted to achieve lung concentrations over
10-fold higher than their reported EC50.

•

Alpha-lipoic acid may reduce short-term mortality rates
In a randomized, single-blind, group sequential, active-controlled study, alpha-lipoic acid use was
associated with lower SOFA score increase compared to the control. Although the 30-day mortality rate
was two-folds higher in placebo group, only borderline statistical difference was evidenced due to the
limited patient number (n=17).

•

Hypothesis: conjugated estrogen therapy could benefit COVID-19 patients
Author advocates for estrogen therapy, citing better female COVID-19 outcomes, animal experiments
where estrogen treatment silences the inflammatory reactions and decreases virus titers, as well as mouse
experiments.

•

Salt water nasal irrigation and gargling reduced coronavirus infections by about 2.5 days
Post-hoc secondary analysis from a randomized controlled trial (n=66) indicates that hypertonic saline nasal
irrigation and gargling (HSNIG) intervention reduces duration of coronavirus upper respiratory tract
infection by an average of 2.5 days. Blocked nose, cough, and hoarseness of voice duration was decreased
through the intervention. With caution due to the low amount of individuals in this study, HSNIG may have
a role in reducing symptoms and duration of illness in COVID-19 and needs to be further studied.

•

Efficacy and safety of integrated traditional Chinese and western medicine
A meta-analysis studied traditional Chinese medicine including Chinese medicine compound drugs (QingFei
TouXie FuZhengFang) and Chinese patent medicine (such as Shufeng Jiedu Capsule, Lianhua Qingwen
granules). Compared with the control group, the overall response rate [RR=1.230, 95%CI (1.113, 1.359),
P<0.001], cure rate [RR=1.604, 95%CI (1.181, 2.177), P=0.002], severity illness rate [RR=0.350, 95%CI
(0.154, 0.792), P=0.012], and hospital stay [WMD=-1.991, 95%CI (-3.278, -0.703), P=0.002] of the
intervention group were better. In addition, Integrated Medicine can improve the disappearance rate of
fever, cough, expectoration, fatigue, chest tightness and anorexia and reduce patients' fever, and fatigue
time (P<0.05).

•

Search for natural inhibitors of SARS-CoV2 protease by molecular docking and simulation
Journal of Biomolecular Structure and Dynamics: The authors performed in silico screening of compounds
from Curcuma longa L. against Mpro protein inhibition. Employing a combination of molecular docking,
scoring functions, and molecular dynamics simulations, 267 compounds were screened by docking on
Mpro crystallographic structure. X-ray crystallographic structure of the SARS-CoV2 Mpro protein
demonstrated the significance of Glu166, Cys141, and His41 residues involved in protein dimerization and
its catalytic function.

